WO2021125246A1 - 蛍光性を有する歯科用硬化性組成物及びその硬化物 - Google Patents
蛍光性を有する歯科用硬化性組成物及びその硬化物 Download PDFInfo
- Publication number
- WO2021125246A1 WO2021125246A1 PCT/JP2020/047055 JP2020047055W WO2021125246A1 WO 2021125246 A1 WO2021125246 A1 WO 2021125246A1 JP 2020047055 W JP2020047055 W JP 2020047055W WO 2021125246 A1 WO2021125246 A1 WO 2021125246A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- curable composition
- group
- fluorescent agent
- dental curable
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*(C)C(CC1O2)=*C=C1N=C(C=CC(C)=CC=C(C)C(F)(F)F)C2=O Chemical compound C*(C)C(CC1O2)=*C=C1N=C(C=CC(C)=CC=C(C)C(F)(F)F)C2=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/65—Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/30—Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
- A61K6/887—Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
Definitions
- the present invention relates to a dental material that can replace a part or all of natural teeth in the field of dentistry, particularly a dental curable composition that can be suitably used as a dental composite resin, a dental mill blank, or the like. ..
- Patent Documents 1 and 2 disclose dental materials containing a phthalate ester-based fluorescent agent such as 2,5-dihydroxydihydroxydiethylterephthalate for the purpose of imparting fluorescence equivalent to that of natural teeth.
- the phthalate ester-based fluorescent agent described in Patent Documents 1 and 2 contains a dental curable composition containing a specific component, specifically, a filler containing zirconia, alumina, or the like. It is known that when coexisting in the composition, the yellowness of the cured product obtained by polymerization curing becomes strong, and it is difficult to reproduce the color tone of natural teeth.
- Patent Document 3 proposes a curable composition in which the contents of an amine compound, a phthalate ester-based fluorescent agent, and an X-ray contrast-enhancing acidic filler are defined.
- an amine compound a phthalate ester-based fluorescent agent
- an X-ray contrast-enhancing acidic filler an X-ray contrast-enhancing acidic filler
- Patent Document 4 proposes an inorganic fluorescent agent that does not discolor even when coexisting with zirconia.
- the fluorescence intensity of an inorganic fluorescent agent decreases as the particle size decreases, and in order to ensure sufficient fluorescence, a dental curable composition is prepared as coarse particles having a size of several ⁇ m. Need to be contained in.
- the inclusion of such coarse inorganic fluorescent particles can cause factors such as a decrease in abrasiveness and mechanical strength, and uneven fluorescence.
- Japanese Unexamined Patent Publication No. 2-23605 Japanese Unexamined Patent Publication No. 2009-280673 Japanese Unexamined Patent Publication No. 2017-141188 JP-A-2010-222466
- the dental curability has sufficient fluorescence, is excellent in aesthetics and durability, has sufficient mechanical strength and X-ray contrast, and does not impair easy polishing.
- the composition and its cured product were not found.
- the present invention has been made to solve the above-mentioned problems of the prior art, and an object of the present invention is to have sufficient fluorescence and to be in harmony with the surroundings so as to be indistinguishable from natural teeth. Highly aesthetic restoration is possible, excellent discoloration resistance under oral environment, accelerated heating conditions, and xenon lamp light exposure conditions, and even under these conditions, fluorescence is not deactivated and restoration is possible. It is an object of the present invention to provide a dental curable composition having sufficient mechanical strength, X-ray contrast property, and good easy-polishing property, and a cured product thereof.
- the dental curable composition containing a compound having a specific structure and the cured product have sufficient fluorescence and are aesthetically pleasing. It has been found that it is excellent in property and durability, has sufficient mechanical strength and X-ray contrast property, and does not impair easy polishing property.
- the present invention includes the following inventions.
- a polymerizable monomer (A), an inorganic filler (B), a polymerization initiator (C), and a fluorescent agent (D) are contained, and the fluorescent agent (D) contains two or more heteroatoms.
- a dental curable composition comprising a 9-11 member benzo-condensed heterocyclic-containing compound (excluding benzimidazole compounds).
- the 9 to 11-membered benzo-condensed heterocycle-containing compound containing two or more heteroatoms contains a fluorescent agent (D-1) which is a benzo-condensed hetero6-membered ring-containing compound containing two heteroatoms. , [1].
- the dental curable composition according to [1].
- Y represents a complex 6-membered ring containing one nitrogen atom and one oxygen atom, and the complex 6-membered ring has at least one oxo group and has a substituent. You may be doing it.
- the fluorescent agent (D-1) is a compound having a site represented by the following general formula (1) or (2). Sex composition.
- the fluorescent agent (D-1) is 2- (2-hydroxyphenyl) -4 (1H) -quinazolinone, 2- (2-hydroxyphenyl) -4H-3,1-benzoxazine-4-one.
- the fluorescent agent (D) further contains a fluorescent agent (D-2) which is a benzo-condensed complex 5-membered ring-containing compound containing one nitrogen atom and one oxygen atom, [2] to [ 9]
- the fluorescent agent (D-2a) is a compound having a site represented by the following general formula (3).
- R 3 represents an aromatic group which may have a substituent or a vinylene group which may have a substituent.
- the inorganic filler (B) is an inorganic filler containing at least one metal compound selected from the group consisting of zirconium oxide, aluminum oxide, ytterbium oxide, and ytterbium fluoride, [1] to [13].
- the dental curable composition according to any one of.
- the present invention it is possible to perform highly aesthetic restoration that has sufficient fluorescence and is indistinguishable from natural teeth and is in harmony with the surroundings.
- Dental that has excellent discoloration resistance under exposure conditions, does not inactivate fluorescence even under these conditions, has sufficient mechanical strength and X-ray contrastability as a restoration, and has good easy polishing property.
- a curable composition for use and a cured product thereof can be provided. Further, the dental curable composition of the present invention and the cured product thereof can be suitably used for dental composite resins, dental mill blanks and the like.
- the dental curable composition of the present invention contains a polymerizable monomer (A), an inorganic filler (B), a polymerization initiator (C), and a fluorescent agent (D), and the fluorescent agent (D) contains.
- A polymerizable monomer
- B inorganic filler
- C polymerization initiator
- D fluorescent agent
- J 9-11-membered benzo-condensed heterocyclic-containing compounds (excluding benzoimidazole compounds) containing two or more heteroatoms.
- a dental composite resin or dentistry having sufficient fluorescence, excellent aesthetics and durability, and sufficient mechanical strength, X-ray contrast, and easy polishing. It is a dental curable composition suitable as a mill blank for use and a cured product thereof.
- Polymerizable monomer (A) As the polymerizable monomer (A) in the dental curable composition of the present invention, known polymerizable monomers used in the dental curable composition can be used, and in particular, radical polymerizable. A monomer can be preferably used. Examples of the radically polymerizable monomer include unsaturated carboxylic acids such as ⁇ -cyanoacrylic acid, (meth) acrylic acid, ⁇ -halogenated acrylic acid, crotonic acid, cinnamic acid, sorbic acid, maleic acid, and itaconic acid.
- unsaturated carboxylic acids such as ⁇ -cyanoacrylic acid, (meth) acrylic acid, ⁇ -halogenated acrylic acid, crotonic acid, cinnamic acid, sorbic acid, maleic acid, and itaconic acid.
- the polymerizable monomer (A) one type may be used alone, or two or more types may be used in combination. Among these, unsaturated carboxylic acid esters and (meth) acrylamide derivatives are preferable, (meth) acrylic acid esters and (meth) acrylamide derivatives are more preferable, and (meth) acrylic acid esters are even more preferable.
- the notation "(meth) acrylic” is used in the meaning which includes both methacryl and acrylic.
- (meth) acrylic monomer is used in the sense of including both a (meth) acrylic acid ester and a (meth) acrylamide derivative. Examples of (meth) acrylic acid esters and (meth) acrylamide derivatives are shown below.
- (I) Monofunctional (meth) acrylic acid ester and (meth) acrylamide derivative For example, methyl (meth) acrylate, isobutyl (meth) acrylate, benzyl (meth) acrylate, dodecyl (meth) acrylate, 2- (N) , N-Dimethylamino) ethyl (meth) acrylate, 2,3-dibromopropyl (meth) acrylate, 3- (meth) acryloyloxypropyltrimethoxysilane, 11- (meth) acryloyloxyundecyltrimethoxysilane, 2- Hydroxyethyl (meth) acrylate, 3-hydroxypropyl (meth) acrylate, 4-hydroxybutyl (meth) acrylate, 6-hydroxyhexyl (meth) acrylate, 10-hydroxydecyl (meth) acrylate, propylene glycol mono (meth) acrylate , Glycer
- Bifunctional (meth) acrylic acid ester For example, aromatic bifunctional (meth) acrylic acid ester, aliphatic bifunctional (meth) acrylic acid ester, and the like can be mentioned.
- aromatic bifunctional (meth) acrylic acid ester examples include 2,2-bis ((meth) acryloyloxyphenyl) propane and 2,2-bis [4- (3-acryloyloxy-2-). Hydroxypropoxy) phenyl] propane, 2,2-bis [4- (3-methacryloyloxy-2-hydroxypropoxy) phenyl] propane (commonly known as Bis-GMA), 2,2-bis (4- (meth) acryloyloxy) Polyethoxyphenyl) propane, 2- (4- (meth) acryloyloxydiethoxyphenyl) -2- (4- (meth) acryloyloxyethoxyphenyl) propane, 2- (4- (meth) acryloyloxydiethoxyphenyl) -2- (4- (meth) acryloyloxytriethoxyphenyl) propane, 2,2-bis (4- (meth) acryloyloxypropoxyphenyl) propane, 2,2-bis (4- (meth) acryloyloxyis
- Examples of the aliphatic bifunctional (meth) acrylic acid ester include glycerol di (meth) acrylate, ethylene glycol di (meth) acrylate, diethylene glycol di (meth) acrylate, triethylene glycol diacrylate, and triethylene glycol.
- Dimethacrylate (commonly known as 3G), propylene glycol di (meth) acrylate, butylene glycol di (meth) acrylate, neopentyl glycol di (meth) acrylate, 1,3-butanediol di (meth) acrylate, 1,5-pentane Didiol di (meth) acrylate, 1,6-hexanediol di (meth) acrylate, 1,10-decanediol di (meth) acrylate, 1,12-dodecanediol di (meth) acrylate, 1,2-bis (3) -(Meta) acryloyloxy-2-hydroxypropyloxy) ethane, tricyclodecanedimethanol di (meth) acrylate, 2,2,4-trimethylhexamethylenebis (2-carbamoyloxyethyl) diacrylate, 2,2 Examples thereof include 4-trimethylhexamethylene bis (2-carbamoyl
- (Iii) Trifunctional or higher (meth) acrylic acid ester
- trimethylolpropane tri (meth) acrylate trimethylol ethanetri (meth) acrylate
- trimethylolmethanetri (meth) acrylate trimethylolmethanetri (meth) acrylate
- pentaerythritol tri (meth) acrylate For example, trimethylolpropane tri (meth) acrylate, trimethylol ethanetri (meth) acrylate, trimethylolmethanetri (meth) acrylate, pentaerythritol tri (meth) acrylate.
- the polymerizable monomer (A) is a dental curable composition having excellent adhesiveness to dentin, metal, ceramics and the like, it is possible to impart adhesiveness to these adherends. It may be preferable to include a functional monomer.
- the functional monomer for example, 2- (meth) acryloyloxyethyl dihydrogen phosphate and 10- (meth) acryloyloxydecyldihydrogen are exhibited from the viewpoint of exhibiting excellent adhesion to dentin and base metal.
- Polymerizable monomer having a phosphate group such as phosphate, 2- (meth) acryloyloxyethylphenylhydrogen phosphate; 11- (meth) acryloyloxyundecane-1,1-dicarboxylic acid, 4- (meth) acryloyloxy
- examples thereof include polymerizable monomers having a carboxylic acid group such as ethoxycarbonylphthalic acid.
- silane coupling agents such as ⁇ - (meth) acryloyloxypropyltrimethoxysilane are mentioned from the viewpoint of being effective for adhesion to ceramics, porcelain, and other dental curable compositions. ..
- the content of the polymerizable monomer (A) in the dental curable composition of the present invention is not particularly limited, but from the viewpoint of operability of the obtained dental curable composition and mechanical strength of the cured product. Based on the total mass of the dental curable composition, it is preferably 1% by mass or more, more preferably 2% by mass or more, further preferably 5% by mass or more, and 8% by mass or more. Further, it may be 15% by mass or more, preferably 70% by mass or less, more preferably 50% by mass or less, further preferably 40% by mass or less, and 30% by mass. The following is particularly preferable.
- the content of the polymerizable monomer (A) in the dental curable composition of the present invention is 3% by mass based on 100 parts by mass of the total mass of the polymerizable monomer (A) and the inorganic filler (B). 4 parts or more is preferable, 4 parts by mass or more is more preferable, 5 parts by mass or more is further preferable, 10 parts by mass or more is particularly preferable, 90 parts by mass or less is preferable, 70 parts by mass or less is more preferable, and 60 parts by mass or less. Is more preferable, and 35 parts by mass or less is particularly preferable.
- the dental curable composition of the present invention contains an inorganic filler (B).
- the average particle size of the inorganic filler (B) is preferably 0.01 ⁇ m or more, more preferably 0.05 ⁇ m or more, further preferably 0.1 ⁇ m or more, and 0.2 ⁇ m or more. It may be 50 ⁇ m or less, more preferably 20 ⁇ m or less, further preferably 10 ⁇ m or less, and particularly preferably 7 ⁇ m or less.
- the average particle size of the inorganic filler (B) is at least the above lower limit, the stickiness of the obtained dental curable composition can be more effectively suppressed and the operability is improved.
- the average particle size of the inorganic filler (B) is not more than the above upper limit, the obtained dental curable composition can more effectively suppress dripping and roughness, and the operability is improved.
- the inorganic filler (B) is agglomerated particles (secondary particles)
- the average particle size of the inorganic filler (B) means the average particle size of the agglomerated particles (secondary particles).
- the average particle size of the inorganic filler (B) can be determined by a laser diffraction / scattering method or an electron microscope observation of the particles.
- the laser diffraction / scattering method is convenient for measuring the particle size of particles of 0.1 ⁇ m or more
- the electron microscope observation is convenient for measuring the particle size of ultrafine particles of less than 0.1 ⁇ m.
- 0.1 ⁇ m is a value measured by the laser diffraction / scattering method.
- the laser diffraction / scattering method uses, for example, a laser diffraction type particle size distribution measuring device (“SALD-2300” manufactured by Shimadzu Corporation, etc.) and ethanol or a 0.2% sodium hexametaphosphate aqueous solution as a dispersion medium on a volume basis. Can be measured.
- SALD-2300 manufactured by Shimadzu Corporation, etc.
- ethanol or a 0.2% sodium hexametaphosphate aqueous solution as a dispersion medium on a volume basis.
- a scanning electron microscope manufactured by Hitachi High-Technologies Corporation, SU3800, S-4000, etc.
- an electron microscope photograph of particles is taken, and the particle size of the particles (200 or more) observed in the unit field of view of the photograph is determined by image analysis type particle size distribution measurement software (Mac-View).
- the particle size is obtained as an arithmetic mean value of the longest length and the shortest length of the particles, and the average primary particle size is calculated from the number of particles and the particle size thereof.
- the average particle size of the inorganic filler (B) can be measured more specifically by the method described in Examples.
- the overall shape of the particles of the inorganic filler (B) is not particularly limited, and can be used as an amorphous or spherical powder.
- a dental curable composition having particularly excellent mechanical strength and abrasion resistance of the cured product can be obtained, and the spherical inorganic filler (B) can be obtained.
- a dental curable composition having a smooth paste property, good spreadability, and excellent operability can be obtained.
- the overall shape of the inorganic filler (B) may be appropriately selected according to the purpose of the dental curable composition.
- various glasses [silica is the main component, and if necessary, oxides such as heavy metals, boron, and aluminum are contained.
- glass powders of common composition such as fused silica, quartz, soda lime silica glass, E glass, C glass, borosilicate glass (Pylex® glass); barium glass (GM27884, 8235, Schott, Inc., E-2000, E-3000, ESSTECH), Strontium borosilicate glass (E-4000, ESSTECH), Lantern glass ceramics (GM31684, Schott), Fluoroaluminosilicate glass (GM35429, G018-091), Dental glass powder such as G018-117 (manufactured by Schott)], various ceramics, alumina, silica-titania, silica-zirconia, silica-ittelvia and other composite oxides, diatomaceous soil, kaolin, clay minerals (montmorillonite, etc.),
- silica as a main component
- inorganic fillers barium glass, alumina, silica-titania, silica-zirconia, silica-itterbia, etc.
- metal compounds such as zirconium oxide, aluminum oxide, and itterbium oxide, which have high X-ray contrast properties, and itterbium fluoride. Is preferably contained.
- the specific surface area of the inorganic filler (B), since there is a tendency to easily abrasive becomes high, preferably at least 10 m 2 / g, more preferably 15 m 2 / g or more, 18m 2 / It is more preferably g or more, particularly preferably 20 m 2 / g or more, and more preferably 300 m 2 / g or less , preferably 250 m 2 / g or less, and 200 m 2 / g or less. Is more preferable, and may be 190 m 2 / g or less, 170 m 2 / g or less, and further 150 m 2 / g or less.
- the specific surface area of the inorganic filler (B) is at least the above lower limit, the easy-to-polish property is further improved. Further, when the specific surface area of the inorganic filler (B) is not more than the above upper limit, the blending amount of the inorganic filler (B) can be increased, and the mechanical strength of the obtained cured product is improved.
- the inorganic filler (B) is agglomerated particles (secondary particles)
- the specific surface area of the inorganic filler (B) means the specific surface area of the agglomerated particles (secondary particles).
- the specific surface area of the inorganic filler (B) can be determined by the BET method. Specifically, for example, it can be measured using a specific surface area measuring device (“BELSORP-mini” series manufactured by Microtrac Bell Co., Ltd., etc.).
- BELSORP-mini specific surface area measuring device
- the inorganic filler (B) is surface-treated as described later, or the inorganic filler (B) is an organic-inorganic composite filler.
- the inorganic filler (B) is treated at 450 ° C. for 4 hours in advance to incinerate it, and then the specific surface area is measured from the viewpoint of eliminating the influence of the organic substance. Is preferable.
- the same ashing is preferable when determining the specific surface area of the inorganic filler (B) contained in the dental curable composition.
- the specific surface area of the inorganic filler (B) can be measured more specifically by the method described in Examples.
- the inorganic filler (B) may be in the form of aggregated particles formed by agglomerating the inorganic filler.
- a commercially available inorganic filler exists as an agglomerate, but 10 mg of the inorganic filler powder is added to 300 mL of water (dispersion medium) to which water or a surfactant such as sodium hexametaphosphate of 5% by mass or less is added.
- water dispersion medium
- the agglomerated particles in the present invention are particles in which particles that are hardly dispersed even under such conditions are strongly agglomerated.
- the particles are heated to near the temperature immediately before melting and contacted.
- a method of heating to the extent that the resulting inorganic filler particles are slightly fused to each other is preferably used.
- the agglomerated form may be formed before heating. Examples of the method include a method in which an inorganic filler is placed in an appropriate container and pressurized, or a method in which the solvent is once dispersed in a solvent and then the solvent is removed by a method such as spray drying.
- silica sol, alumina sol, titania sol, zirconia sol or the like produced by a wet method is used, and this is freeze-dried, spray-dried or the like.
- sol examples include silica spherical fine particles (trade name "Sea Hoster (registered trademark)” (KE series, surface treatment type, etc .; above, manufactured by Nippon Catalyst Co., Ltd.)), silica organosol (trade name "OSCAL (registered trademark)”).
- Titania sol (trade name“ QUEEN TITANIC ”series; manufactured by Nissan Chemical Co., Ltd.), silica sol (trade name“ Snowtex (registered trademark) ”; manufactured by Nissan Chemical Co., Ltd.), alumina sol (manufactured by Nissan Chemical Co., Ltd.) Product names "Alumina Sol-100", “Alumina Sol-200", “Alumina Sol-520”; above, manufactured by Nissan Chemical Co., Ltd.), Zirconia Sol (Product name "Nano Teen (registered trademark) ZR” series; manufactured by Nissan Chemical Co., Ltd.) And so on.
- the shape of the inorganic filler particles is not particularly limited, and can be appropriately selected and used.
- the inorganic filler (B) may be contained in the dental curable composition as an organic-inorganic composite filler.
- the organic-inorganic composite filler refers to a filler containing the inorganic filler and a polymer of a polymerizable monomer.
- an inorganic filler having an average particle size of 5 ⁇ m or less is dispersed in the organic matrix, and the average particle size of the inorganic filler is more preferably 2 ⁇ m or less. It is more preferably 1 ⁇ m or less.
- the method for producing the organic-inorganic composite filler in the present invention is not particularly limited.
- a known polymerizable monomer and a known polymerization initiator are added in advance to the inorganic filler to form a paste, and then a solution is obtained. It may be produced by polymerization, suspension polymerization, emulsion polymerization, bulk polymerization, and pulverization.
- the refractive index of the inorganic filler (B) is not particularly limited, but the transparency of the obtained cured product can be obtained by approximating the refractive index of the components other than the inorganic filler (B) in the dental curable composition. It becomes easy to raise it. From this, the refractive index of the inorganic filler (B) is preferably 1.45 or more, more preferably 1.50 or more, further preferably 1.51 or more, and 1 It is preferably .63 or less, more preferably 1.60 or less, and even more preferably 1.58 or less. The refractive index of the inorganic filler (B) can be controlled by adjusting the type and ratio of the metal elements contained therein.
- the inorganic filler (B) does not have to be surface-treated, but the surface of the inorganic filler (B) is hydrophobized to improve the affinity with the polymerizable monomer (A), and the inorganic filler (B) (inorganic filler (B))
- the surface treatment is preferable because the blending amount of B) can be increased.
- the surface treatment can be performed using a surface treatment agent.
- the type of the surface treatment agent is not particularly limited, and a known surface treatment agent can be used.
- a silane coupling agent, an organic titanium-based coupling agent, an organic zirconium-based coupling agent, and an organoaluminum-based coupling agent. Etc. can be used.
- the surface treatment agent one type may be used alone, or two or more types may be used in combination.
- a silane coupling agent is preferable from the viewpoint of affinity and availability of the polymerizable monomer (A) and the inorganic filler (B).
- the type of the silane coupling agent is not particularly limited, but it is preferably a compound represented by the following general formula (4).
- R 4 is a hydrogen atom or a methyl group
- R 5 is an oxygen atom, a sulfur atom, or -NR 8 - a
- R 8 is a hydrogen atom or an aliphatic group having 1 to 8 carbon atoms ( It may be linear, branched or cyclic)
- R 6 is a hydrolyzable group
- R 7 is a hydrocarbon group with 1 to 6 carbon atoms
- p is an integer of 1 to 3.
- Q is an integer from 1 to 13, and a plurality of R 6 and R 7 existing may be the same or different from each other.
- R 4 is a hydrogen atom or a methyl group, and is preferably a methyl group.
- R 5 is an oxygen atom, a sulfur atom, or -NR 8 - and is preferably an oxygen atom.
- the R 8 is a hydrogen atom or an aliphatic group having 1 to 8 carbon atoms (which may be linear, branched or cyclic), and is represented by the R 8 is an aliphatic group having 1 to 8 carbon atoms.
- the group may be either a saturated aliphatic group (alkyl group, cycloalkylene group (cyclohexyl group, etc.), etc.) or an unsaturated aliphatic group (alkenyl group, alkynyl group, etc.), and is available and easy to produce. From the viewpoint of chemical stability and the like, a saturated aliphatic group is preferable, and an alkyl group is more preferable.
- alkyl group examples include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group and n-.
- examples thereof include a hexyl group, an n-heptyl group, a 2-methylhexyl group, and an n-octyl group.
- R 8 is preferably a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, more preferably a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, and even more preferably a hydrogen atom.
- examples of the hydrolyzable group represented by R 6 include an alkoxy group such as a methoxy group, an ethoxy group and a butoxy group; a halogen atom such as a chlorine atom and a bromine atom; and an isocyanate group. Can be mentioned. In the case where R 6 there are a plurality of the R 6 may be the same or different from each other. Among these, R 6 is preferably an alkoxy group, more preferably a methoxy group or an ethoxy group, and even more preferably a methoxy group.
- examples of the hydrocarbon group having 1 to 6 carbon atoms represented by R 7 include an alkyl group having 1 to 6 carbon atoms (which may be cyclic) and an alkenyl group having 2 to 6 carbon atoms. (It may be cyclic), an alkynyl group having 2 to 6 carbon atoms, and the like. In the case where R 7 there are a plurality of said R 7 may being the same or different.
- alkyl group having 1 to 6 carbon atoms examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group and an n-pentyl group. , Isopentyl group, neopentyl group, tert-pentyl group, n-hexyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and the like.
- alkenyl group having 2 to 6 carbon atoms examples include a vinyl group, an allyl group, a 1-methylvinyl group, a 1-propenyl group, a butenyl group, a pentanyl group, a hexenyl group, a cyclopropenyl group, a cyclobutenyl group and a cyclopentenyl group. , Cyclohexenyl group and the like.
- alkynyl group having 2 to 6 carbon atoms examples include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 1-methyl-2-propynyl, 2-butynyl, 3-butynyl, 1-pentynyl and 1-.
- p is an integer of 1 to 3, preferably 2 or 3, and more preferably 3.
- q is an integer of 1 to 13, preferably an integer of 2 to 12, and more preferably an integer of 3 to 11.
- silane coupling agent represented by the general formula (4) examples include methacryloyloxymethyltrimethoxysilane, 2-methacryloyloxyethyltrimethoxysilane, 3-methacryloyloxypropyltrimethoxysilane, and 4-methacryloyloxy.
- silane coupling agent may be used alone, or two or more types may be used in combination.
- 3-methacryloyloxypropyltrimethoxysilane is preferable from the viewpoint of availability, and from the viewpoint of further enhancing the affinity between the polymerizable monomer (A) and the inorganic filler (B), it is preferable.
- 8-Methoxyloyloxyoctyltrimethoxysilane, 9-methacryloyloxynonyltrimethoxysilane, 10-methacryloyloxydecyltrimethoxysilane, 11-methacryloyloxyundecyltrimethoxysilane are preferred.
- the surface treatment method is not particularly limited, and a known method can be applied.
- the amount of the surface treatment agent used is not particularly limited, but the amount of the surface treatment agent used can be, for example, 1 part by mass or more with respect to 100 parts by mass of the filler before the surface treatment, and the amount used is 5 parts by mass. It is preferably parts or more, more preferably 6 parts by mass or more, further preferably 8 parts by mass or more, particularly preferably 10 parts by mass or more, and most preferably 20 parts by mass or more. It is preferable, and it is preferably 50 parts by mass or less, more preferably 45 parts by mass or less, and further preferably 40 parts by mass or less.
- the amount used is at least the above lower limit, the mechanical strength of the obtained cured product is more likely to be improved, and when the amount used is not more than the above upper limit, the cured product obtained by the surplus surface treatment agent is used. It is possible to suppress a decrease in mechanical strength of.
- the content of the inorganic filler (B) in the dental curable composition of the present invention is not particularly limited, but can be obtained.
- the content is preferably 10% by mass or more, preferably 30% by mass or more, based on the total mass of the dental curable composition. It is more preferably 50% by mass or more, particularly preferably 65% by mass or more, preferably 97% by mass or less, and more preferably 96% by mass or less. , 95% by mass or less, and particularly preferably 90% by mass or less.
- the content of the inorganic filler (B) is equal to or higher than the above lower limit, the mechanical strength of the cured product is improved, and the stickiness of the dental curable composition is more effectively suppressed to improve its operability. .. Further, when the content of the inorganic filler (B) is not more than the above upper limit, it is possible to prevent the obtained dental curable composition from becoming excessively hard, and the operability is improved.
- the content of the inorganic filler (B) in the dental curable composition of the present invention is 10 parts by mass or more based on 100 parts by mass of the total mass of the polymerizable monomer (A) and the inorganic filler (B).
- It is preferably 30 parts by mass or more, more preferably 50 parts by mass or more, particularly preferably 65 parts by mass or more, and preferably 97 parts by mass or less. , 96 parts by mass or less, more preferably 95 parts by mass or less, and particularly preferably 90 parts by mass or less.
- the dental curable composition of the present invention may contain an organic filler.
- organic filler include acrylic polymers such as polymethyl methacrylate, ethyl polymethacrylate, methyl methacrylate-ethyl methacrylate copolymer, crosslinked polymethylmethacrylate, crosslinked polyethyl methacrylate, and polyamide; poly.
- the organic filler is not particularly limited, and the particle size of the organic filler can be appropriately selected and used. From the viewpoint of handleability and mechanical strength of the obtained composition, the average particle size of the organic filler is preferably 0.001 to 50 ⁇ m, more preferably 0.001 to 10 ⁇ m. Examples of the method for measuring the average particle size of the organic filler are the same as the average particle size of the inorganic filler (B).
- the dental curable composition of the present invention contains a polymerization initiator (C).
- a polymerization initiator used in the general industry can be selected and used, and among them, a polymerization initiator used for dental use is preferably used.
- a photopolymerization initiator and a chemical polymerization initiator are preferably used.
- the polymerization initiator (C) one type may be used alone, or two or more types may be used in combination as appropriate.
- photopolymerization initiator examples include (bis) acylphosphine oxides, ketals, ⁇ -diketones, coumarin compounds and the like.
- the acylphosphine oxides include 2,4,6-trimethylbenzoyldiphenylphosphine oxide, 2,6-dimethoxybenzoyldiphenylphosphine oxide, and 2,6-dichlorobenzoyldiphenylphosphine oxide, 2 , 4,6-trimethylbenzoylmethoxyphenylphosphine oxide, 2,4,6-trimethylbenzoylethoxyphenylphosphine oxide, 2,3,5,6-tetramethylbenzoyldiphenylphosphine oxide, benzoyldi (2,6-dimethylphenyl) phosphonate And these salts (sodium salt, potassium salt, ammonium salt, etc.) and the like.
- bisacylphosphine oxides include bis (2,6-dichlorobenzoyl) phenylphosphine oxide, bis (2,6-dichlorobenzoyl) -2,5-dimethylphenylphosphine oxide, and bis (2,6-dichlorobenzoyl)-.
- ketals examples include benzyldimethyl ketal and benzyldiethyl ketal.
- ⁇ -diketones examples include diacetyl, benzyl, camphorquinone, 2,3-pentadione, 2,3-octadione, 9,10-phenanthrenequinone, 4,4'-oxybenzyl, acenaphthenicone and the like. ..
- camphorquinone is particularly preferable from the viewpoint of having a maximum absorption wavelength in the visible light region.
- Examples of the coumarin compound include 3,3'-carbonylbis (7-diethylamino kumarin), 3- (4-methoxybenzoyl) coumarin, 3-thienoyl coumarin, 3-benzoyl-5,7-dimethoxy kumarin, 3-.
- 3,3'-carbonylbis (7-diethylaminocoumarin) and 3,3'-carbonylbis (7-dibutylaminocoumarin) are particularly preferable.
- photopolymerization initiators selected from the group consisting of (bis) acylphosphine oxides, ⁇ -diketones, and coumarin compounds
- photocurability in the visible and near-ultraviolet regions can be achieved.
- a dental curable composition that is excellent and exhibits sufficient photocurability can be obtained by using any light source of a halogen lamp, a light emitting diode (LED), and a xenon lamp.
- Organic peroxide is preferably used as the chemical polymerization initiator.
- the organic peroxide used in the above-mentioned chemical polymerization initiator is not particularly limited, and known ones can be used.
- Typical organic peroxides include ketone peroxides, hydroperoxides, diacyl peroxides, dialkyl peroxides, peroxyketals, peroxyesters, peroxydicarbonates and the like.
- ketone peroxide examples include methyl ethyl ketone peroxide, methyl isobutyl ketone peroxide, methyl cyclohexanone peroxide, and cyclohexanone peroxide.
- hydroperoxide examples include 2,5-dimethylhexane-2,5-dihydroperoxide, diisopropylbenzene hydroperoxide, cumene hydroperoxide, t-butyl hydroperoxide, 1,1,3,3-tetramethylbutyl hydroperoxide and the like. Be done.
- diacyl peroxide examples include acetyl peroxide, isobutyryl peroxide, benzoyl peroxide, decanoy peroxide, 3,5,5-trimethylhexanoyl peroxide, 2,4-dichlorobenzoyl peroxide, and lauroyl peroxide.
- dialkyl peroxide examples include di-t-butyl peroxide, dicumyl peroxide, t-butyl cumyl peroxide, 2,5-dimethyl-2,5-di (t-butylperoxy) hexane, and 1,3-bis (t-). Butylperoxyisopropyl) benzene, 2,5-dimethyl-2,5-di (t-butylperoxy) -3-hexine and the like can be mentioned.
- Peroxyketals include 1,1-bis (t-butylperoxy) -3,3,5-trimethylcyclohexane, 1,1-bis (t-butylperoxy) cyclohexane, and 2,2-bis (t-butylperoxy). Butane, 2,2-bis (t-butylperoxy) octane, 4,4-bis (t-butylperoxy) valeric acid-n-butyl ester and the like can be mentioned.
- Peroxyesters include ⁇ -cumylperoxyneodecanoate, t-butylperoxyneodecanoate, t-butylperoxypivalate, 2,2,4-trimethylpentylperoxy-2-ethylhexanoate, t-.
- peroxydicarbonate examples include di-3-methoxyperoxydicarbonate, di (2-ethylhexyl) peroxydicarbonate, bis (4-t-butylcyclohexyl) peroxydicarbonate, diisopropylperoxydicarbonate, and di-n-propylperoxydi. Examples thereof include carbonate, di (2-ethoxyethyl) peroxydicarbonate, and diallylperoxydicarbonate.
- diacyl peroxide is preferably used from the viewpoint of overall balance of safety, storage stability and radical generation ability, and among them, benzoyl peroxide is particularly preferably used.
- the content of the polymerization initiator (C) in the dental curable composition of the present invention is not particularly limited, but from the viewpoint of curability of the obtained dental curable composition and the like, the polymerizable monomer (A) It is preferably 0.001 part by mass or more, more preferably 0.01 part by mass or more, further preferably 0.02 part by mass or more, and 0. It is particularly preferable that the amount is 1 part by mass or more. Further, if the content of the polymerization initiator (C) is too large, precipitation from the dental curable composition may occur. Therefore, the content is the total mass of the polymerizable monomer (A).
- 100 parts by mass it is preferably 30 parts by mass or less, more preferably 20 parts by mass or less, further preferably 15 parts by mass or less, and particularly preferably 10 parts by mass or less. It may be 5 parts by mass or less and 2 parts by mass or less.
- the dental curable composition of the present invention contains a fluorescent agent (D).
- the fluorescent agent (D) contains a 9 to 11-membered benzo-condensed heterocyclic compound containing two or more heteroatoms (excluding benzimidazole compounds).
- the hetero atom include an oxygen atom, a sulfur atom and a nitrogen atom, and an oxygen atom and a nitrogen atom are preferable.
- the two or more heteroatoms contained in the benzo-condensed heterocyclic compound at least one is preferably a nitrogen atom.
- the benzo-condensed heterocycle-containing compound is a fluorescent agent (D-1) which is a benzo-condensed heterocyclic 6-membered ring-containing compound containing two heteroatoms (hereinafter, also simply referred to as “fluorescent agent (D-1)”. ) Is preferable.
- the benzo-condensed complex 6-membered ring-containing compound has a complex 6-membered ring containing two heteroatoms and a condensed ring in which a benzene ring is condensed.
- the fluorescent agent (D-1) include a compound containing a benzodiadinone skeleton and a compound containing a benzoxazine skeleton.
- the compound containing a benzodiadinone skeleton includes a compound containing a quinazolinone skeleton (D-1a), a compound containing a cinnolinone skeleton (D-1b), a compound containing a phthaladinone skeleton (D-1c), and a quinoxalinone skeleton (D-1d).
- D-1a quinazolinone skeleton
- D-1b a compound containing a cinnolinone skeleton
- D-1c a compound containing a phthaladinone skeleton
- D-1d quinoxalinone skeleton
- the quinazolinone skeleton (D-1a) is preferable.
- the fluorescent agent (D-1) it has sufficient fluorescence, high aesthetics, and excellent discoloration resistance under oral environment, accelerated heating conditions, and xenon lamp light exposure conditions.
- dental curable composition suitable as a dental composite resin and a dental mill blank whose fluorescence is not inactivated even under the above conditions, and a cured product thereof.
- the reason why the above-mentioned excellent effects are exhibited by the dental curable composition of the present invention and the cured product thereof is not always clear, but two or more such as a benzodiadinone skeleton or a benzoxazine skeleton. It is considered that this is because the stability of the 9 to 11-membered benzo-fused heterocyclic skeleton containing a hetero atom is high.
- the fluorescent agent (D-1) is preferably a compound containing a benzodiadinone skeleton (particularly preferably a quinazolinone skeleton) or a compound containing at least one skeleton of a benzoxazine skeleton, and a compound containing a quinazolinone skeleton (D-1a). Is more preferable.
- the fluorescent agent (D-1) may have one benzodiadinone skeleton (particularly preferably a quinazolinone skeleton) or a benzoxazine skeleton, or may have a plurality of benzodiadinone skeletons.
- the benzodiadinone skeleton is represented by the following general formula (5).
- the number of oxo groups is not particularly limited, and is 1 or 2, preferably 1.
- X represents any part of the following formulas (X-1) to (X-5), and formulas (X-3) and (X-4) are preferable, and formula (X-3). Is more preferable.
- the benzoxazinone skeleton is represented by the following general formula (6).
- Y represents a complex 6-membered ring containing one nitrogen atom and one oxygen atom, and the complex 6-membered ring has at least one oxo group and is a substituent. May have.
- Y is preferably an aromatic heterocycle.
- the number of oxo groups is not particularly limited, and is 1 or 2, preferably 1.
- Y represents any part of the following formulas (Y-1) to (Y-6), and formulas (Y-5) and (Y-6) are preferable.
- the benzodiadinone skeleton (particularly preferably a quinazolinone skeleton) and the benzoxazine skeleton may or may not have a substituent.
- substituents examples include a hydroxyl group; a thiol group; a nitro group; a halogen atom; an alkyl group having 1 to 10 carbon atoms; an alkenyl group such as a vinyl group and an allyl group; an alkoxy group having 1 to 10 carbon atoms; a phenyl group.
- Aromatic groups such as naphthyl groups and styryl groups; alkyl halides having 1 to 10 carbon atoms substituted with halogen atoms; acyl groups such as acetyl groups; amino groups; alkylamino groups such as methylamino groups; dimethylamino groups Dialkylamino groups such as; aminoalkyl groups such as aminoethyl groups; carboxy groups; alkoxycarbonyl groups such as methoxycarbonyl groups; alkoxycarbonylalkyl groups such as methoxycarbonylmethyl groups; alkyloxyalkyl groups such as methyloxymethyl groups; methylthio Alkoxythioalkyl groups such as methyl groups; aminoalkylaminoalkyl groups such as aminomethylaminomethyl groups; alkylcarbonyloxy groups such as methylcarbonyloxy groups; arylalkoxyalkoxyalkyl groups such as benzyloxyethoxyethyl groups; hydroxyethoxymethyl
- fluorescent agents (D-1) compounds having a site represented by the following general formula (1) or (2) are preferable.
- R 1 in the general formulas (1) and (2) is an oxygen atom or -NH-, and R 2 represents an aromatic group which may have a substituent.
- Examples of the aromatic group represented by R 2 include an aryl group such as a phenyl group, a biphenylyl group, a terphenylyl group, a styryl group, a naphthyl group, an anthryl group, an acenaphthenyl group, a fluorenyl group, a phenanthryl group and an indenyl group; Aralkyl such as 1-phenylethyl group, 2-phenylpropyl group, 3-phenylpropyl group, phenylbutyl group, 1-methyl-3-phenylpropyl group, naphthylmethyl group, naphthylethyl group, naphthylpropyl group, naphthylbutyl group Group: Pyrenyl group, pyrimidyl group, furanyl group, pyronyl group, thienyl group, quinolyl group, benzofuranyl group, benzothiophenyl group,
- the aromatic group represented by R 2 may or may not have a substituent.
- the substituent include the above-mentioned benzodiadinone skeleton and the substituent described as a substituent of the benzoxazine skeleton.
- substituents from the viewpoint of fluorescence and durability, a hydroxyl group, a halogen atom, an alkyl group having 1 to 3 carbon atoms, an alkyl halide group having 1 to 3 carbon atoms substituted with a halogen atom, a dimethylamino group, and the like.
- a carboxy group and a benzenesulfonamide group are preferable.
- the number of the substituents may be 1 to 20, 1 to 10, 1 to 6, or 1 to 3.
- the substituents may be combined, for example, the substituents may or may not be substituted by yet another substituent.
- fluorescent agents (D-1) from the viewpoint of fluorescence and durability, 2- (2-Hydroxyphenyl) -4 (1H) -quinazolinone, 2- (2-Hydroxyphenyl) -4H-3,1-benzoxazine-4-one, N- [2- (4 (1H) -quinazolinone-2-yl) phenyl] benzenesulfonamide, N- [2- (4-oxo-1,3-benzoxazine-2-yl) phenyl] benzenesulfonamide, 7-Dimethylamino-3- [2- [4- (trifluoromethyl) phenyl] ethenyl] -2H-1,4-benzoxazine-2-one, 7-Dimethylamino-3- [2- [2,3,4,5,6-pentafluorophenyl] ethenyl] -2H-1,4-benzoxazine-2-one, 7--
- the content of the fluorescent agent (D-1) in the dental curable composition of the present invention is not particularly limited, but in order for the obtained dental curable composition to exhibit sufficient fluorescence, a polymerizable monomer It is preferably 0.0001 parts by mass or more, more preferably 0.0002 parts by mass or more, and 0.0005 parts by mass with respect to 100 parts by mass of the total mass of (A) and the inorganic filler (B). It is more preferably 0.001 part by mass or more, and more preferably 0.0005 part by mass or more with respect to 100 parts by mass of the total mass of the polymerizable monomer (A). , 0.001 part by mass or more, more preferably 0.002 part by mass or more, and particularly preferably 0.005 part by mass or more.
- the total mass of the inorganic filler (B) is preferably 3 parts by mass or less, more preferably 1 part by mass or less, still more preferably 0.5 parts by mass or less, based on 100 parts by mass. It is particularly preferably 0.1 part by mass or less, preferably 5 parts by mass or less, and more preferably 1 part by mass or less, based on 100 parts by mass of the total mass of the polymerizable monomer (A). It is more preferably 0.5 parts by mass or less, and particularly preferably 0.2 parts by mass or less.
- the fluorescent agent (D-1) one type may be used alone, or two or more types may be used in combination. By using two or more of them together, the fluorescence color of the cured product of the dental curable composition of the present invention can be arbitrarily adjusted according to the mixing ratio thereof, and the fluorescence closer to that of natural teeth can be reproduced, which is highly aesthetically pleasing.
- Dental curable compositions can be provided.
- the dental curable composition of the present invention is a benzo-condensed complex 5-membered ring-containing compound containing one nitrogen atom and one oxygen atom in addition to the fluorescent agent (D-1) as the fluorescent agent (D). It is preferable to further contain the fluorescent agent (D-2) which is.
- the benzo-condensed complex 5-membered ring-containing compound has a condensed ring in which a complex 5-membered ring containing one nitrogen atom and one oxygen atom and a benzene ring are condensed.
- Examples of the fluorescent agent (D-2) include a fluorescent agent (D-2a), which is a compound containing a benzoxazole skeleton (hereinafter, also simply referred to as “fluorescent agent (D-2a)”), and a compound containing a benzoxazole skeleton.
- Fluorescent agent (D-2b) which is a compound containing a benzoxazole skeleton, is particularly preferable.
- the fluorescent agent (D-2a) means a compound containing a benzoxazole skeleton represented by the following formula (7). Further, the fluorescent agent (D-2a) may have a plurality of benzoxazole skeletons.
- the benzoxazole skeleton may or may not have a substituent. Examples of the substituent include the above-mentioned quinazolinone skeleton and the substituent described as the substituent of the benzoxazine skeleton.
- a hydroxyl group, a halogen atom, and an alkyl group having 1 to 3 carbon atoms are preferable from the viewpoint of fluorescence and durability.
- the number of the substituents may be 1 to 20, 1 to 10, 1 to 6, or 1 to 3.
- the substituent may or may not further have a substituent.
- a compound having a site represented by the following general formula (3) is preferable from the viewpoint of fluorescent color and durability.
- R 3 represents an aromatic group which may have a substituent or a vinylene group which may have a substituent.
- Examples of the aromatic group represented by R 3 include a divalent group of the group exemplified as the aromatic group represented by R 2 in the general formulas (1) and (2). Of these, a phenylene group, a naphthylene group, and a thienylene group are preferable.
- the compound represented by the general formula (3) may or may not have a substituent.
- substituents include the same substituents as those of the above-mentioned benzoxazole skeleton.
- fluorescent agents (D-2a) of the compound containing the benzoxazole skeleton from the viewpoint of fluorescence and durability, 1,4-bis (2-benzoxazolyl) naphthalene, 4,4'-bis (2-benzoxazoleyl) stilbene, 1,2-bis (5-methylbenzoxazole-2-yl) ethene, 4,4'-bis (5-methyl-2-benzoxazolyl) stilbene, 4- (2-benzoxazolyl) -4'-(5-methyl-2-benzoxazolyl) stilbene, 2,5-bis (benzoxazole-2-yl) thiophene, 2,5-bis (5-tert-butyl-2-benzoxazolyl) thiophene, Is preferable.
- the content of the fluorescent agent (D-2) in the dental curable composition of the present invention is not particularly limited, but in order for the obtained dental curable composition to exhibit sufficient fluorescence, a polymerizable monomer It is preferably 0.0001 parts by mass or more, more preferably 0.0002 parts by mass or more, and 0.0005 parts by mass with respect to 100 parts by mass of the total mass of (A) and the inorganic filler (B). The above is more preferable, and 0.001 part by mass or more is particularly preferable.
- the content of the fluorescent agent (D-2) was set to 0. With respect to 100 parts by mass of the total mass of the polymerizable monomer (A) so that the obtained dental curable composition exhibited sufficient fluorescence.
- the total mass of the monomer (A) and the inorganic filler (B) is 100 parts by mass or less, preferably 3 parts by mass or less, more preferably 1 part by mass or less, and 0.5 parts by mass or less. Is more preferable, and 0.1 parts by mass or less is particularly preferable.
- the content of the fluorescent agent (D-2) may deteriorate the aesthetics of the dental curable composition, 5 mass by mass with respect to 100 parts by mass of the total mass of the polymerizable monomer (A). It is preferably parts or less, more preferably 1 part by mass or less, further preferably 0.5 parts by mass or less, and particularly preferably 0.2 parts by mass or less.
- the fluorescent agent (D-2) one type may be used alone, or two or more types may be used in combination.
- the polymerizable monomer (A), the inorganic filler (B), the polymerization initiator (C), and the fluorescent agent (D) are included, and the number of the fluorescent agents (D) is two or more.
- the 9-11-membered benzo-condensed heterocycle-containing compound containing a heteroatom (excluding the benzoimidazole compound) and the 9-11-membered benzo-condensed heterocycle-containing compound containing the two or more heteroatoms is a fluorescent agent (D-).
- a fluorescent agent D-
- examples thereof include dental curable compositions that do not contain 1) and contain a fluorescent agent (D-2).
- the dental curable composition of the present invention may contain a fluorescent agent (D-3) containing a phthalate ester as long as the effects of the present invention are exhibited.
- the fluorescent agent (D-3) containing the phthalate ester is distinguished from the fluorescent agents (D-1) and (D-2).
- the fluorescent agent (D-3) containing a phthalate ester is represented by the following general formula (8). (In the formula, R 10 and R 11 are independently alkyl groups, R 12 is a hydrogen atom, an amino group, or a hydroxyl group, and R 13 is an amino group or a hydroxyl group.)
- alkyl group those having 1 to 3 carbon atoms such as a methyl group, an ethyl group, an n-propyl group and an i-propyl group are preferable, and those having 1 to 2 carbon atoms are particularly preferable.
- the content of the fluorescent agent (D-3) in the dental curable composition of the present invention can cause a color change (yellowing) of the dental curable composition
- the content of the fluorescent agent (D-3) is different from that of the polymerizable monomer (A). It is preferably 0.5 parts by mass or less, more preferably 0.1 parts by mass or less, and 0.01 parts by mass or less with respect to 100 parts by mass of the total mass of the inorganic filler (B). Is more preferable, and it is particularly preferable that the content is not contained. Since the content of the fluorescent agent (D-3) can cause a color change (yellowing) of the dental curable composition, it is 0 with respect to 100 parts by mass of the total mass of the polymerizable monomer (A).
- fluorescent agent (D-3) is preferably 1 part by mass or less, more preferably 0.01 part by mass or less, further preferably 0.001 part by mass or less, and particularly preferably not contained.
- One type of fluorescent agent (D-3) may be used alone, or two or more types may be used in combination.
- Preferable embodiments of the present invention include dental curable compositions in which the fluorescent agent (D) does not contain the fluorescent agent (D-3).
- the fluorescent agent (D) of the dental curable composition of the present invention is a fluorescent agent (D-4) other than the fluorescent agents (D-1), (D-2), and (D-3). It may be included.
- fluorescent agent (D-4) a fluorescent agent used in the general industry can be selected and used, and among them, a fluorescent agent used for dental use is preferably used.
- Such fluorescent agents (D-4) are roughly classified into organic fluorescent agents and inorganic fluorescent agents.
- One type of fluorescent agent (D-4) may be used alone, or two or more types may be used in combination.
- organic fluorescent agent examples include a coumarin-based fluorescent agent, a naphthalimide-based fluorescent agent, a xanthene-based fluorescent agent, a thioxanthene-based fluorescent agent, a naphtholactam-based fluorescent agent, a thiazine-based fluorescent agent, an oxazole-based fluorescent agent, and a furan-based fluorescent agent.
- Benzofuran fluorescent agent pyrazoline fluorescent agent, stillben fluorescent agent, distyrylbenzene fluorescent agent, distyrylbiphenyl fluorescent agent, benzoimidazole compound, 1,3,5-triazine-2-yl derivative, arylbenzoguanamine
- Benzofuran fluorescent agent pyrazoline fluorescent agent, stillben fluorescent agent, distyrylbenzene fluorescent agent, distyrylbiphenyl fluorescent agent, benzoimidazole compound, 1,3,5-triazine-2-yl derivative, arylbenzoguanamine
- examples thereof include a polycyclic fluorescent agent and a polycyclic aromatic hydrocarbon-based fluorescent agent.
- Examples of the inorganic fluorescent agent include Y 2 SiO 5 : Ce, Y 2 SiO 5 : Tb, (Y, Gd, Eu) BO 3 , Y 2 O 3 : Eu, YAG: Ce, ZnGa 2 O 4 : Zn.
- BaMgAl 10 O 17 Eu
- BaMgAl 10 O 17 Eu
- (SrCaBaMg) 5 (PO 4 ) 3 Cl Eu
- Zn 2 SiO 4 Mn
- BaMg 2 Al 16 O 27 Eu
- BaMg 2 Al 16 O 27 Eu
- Mn BaMg 2 Al 16 O 27
- LaPO 4 Ce
- LaPO 4 Tb
- LaPO 4 Ce
- Y 2 O 2 S Eu
- Y 2 SiO 5 Ce is preferable from the viewpoint of fluorescent color.
- the dental curable composition of the present invention may further contain a polymerization accelerator (E).
- a polymerization accelerator examples include amines, sulfinic acid and salts thereof, barbituric acid derivatives, borate compounds, triazine compounds, copper compounds, tin compounds, vanadium compounds, halogen compounds, aldehydes, thiol compounds, sulfites, and hydrogen sulfites. , Thiourea compounds and the like.
- the polymerization accelerator (E) one type may be used alone, or two or more types may be used in combination.
- the polymerization initiator (C) comprises a photopolymerization initiator, further comprising a polymerization accelerator (E), wherein the polymerization accelerator (E) is a tertiary amine, dental curability.
- the composition is mentioned.
- a tertiary aromatic amine is preferable.
- the dental curable composition of the preferred embodiment is more suitable as a dental composite resin.
- Amines are divided into aliphatic amines and aromatic amines.
- the aliphatic amine include primary aliphatic amines such as n-butylamine, n-hexylamine and n-octylamine; and secondary aliphatic amines such as diisopropylamine, dibutylamine and N-methylethanolamine; N-Methyldiethanolamine, N-ethyldiethanolamine, Nn-butyldiethanolamine, N-lauryldiethanolamine, 2- (dimethylamino) ethylmethacrylate, N-methyldiethanolaminedimethacrylate, N-ethyldiethanolaminedimethacrylate, triethanolamine monomethacrylate , Triethanolamine dimethacrylate, triethanolamine trimethacrylate, triethanolamine, trimethylamine, triethylamine, tributylamine and other tertiary aliphatic amines.
- aromatic amine examples include N, N-bis (2-hydroxyethyl) -3,5-dimethylaniline, N, N-bis (2-hydroxyethyl) -p-toluidine, and N, N-bis. (2-Hydroxyethyl) -3,4-dimethylaniline, N, N-bis (2-hydroxyethyl) -4-ethylaniline, N, N-bis (2-hydroxyethyl) -4-isopropylaniline, N, N-bis (2-hydroxyethyl) -4-t-butylaniline, N, N-bis (2-hydroxyethyl) -3,5-di-isopropylaniline, N, N-bis (2-hydroxyethyl)- 3,5-Di-t-butylaniline, N, N-dimethylaniline, N, N-dimethyl-p-toluidine, N, N-dimethyl-m-toluidine, N, N-die
- sulfinic acid and salts thereof include p-toluenesulfinic acid, sodium p-toluenesulfinate, potassium p-toluenesulfinate, lithium p-toluenesulfinate, calcium p-toluenesulfinate, benzenesulfinic acid, and benzenesulfin.
- barbituric acid derivatives include barbituric acid, 1,3-dimethylbarbituric acid, 1,3-diphenylbarbituric acid, 1,5-dimethylbarbituric acid, 5-butylbarbituric acid, and 5-ethylbarbituric acid.
- Particularly suitable barbituric acid derivatives include 5-butyl barbituric acid, 1,3,5-trimethylbarbituric acid, 1-cyclohexyl-5-ethyl barbituric acid, 1-benzyl-5-phenylbarbituric acid, and the like. And the sodium salts of these barbiturates.
- an aryl borate compound is preferable.
- the aryl borate compound include a borate compound having 1 to 4 aryl groups in one molecule.
- a borate compound having 3 or 4 aryl groups in one molecule is preferable from the viewpoint of storage stability.
- the borate compound having three aryl groups in one molecule include monoalkyltriphenylboron, monoalkyltri (p-chlorophenyl) boron, monoalkyltri (p-fluorophenyl) boron, and monoalkyltri [3].
- 5-bis (trifluoromethyl) phenyl] boron monoalkyltri [3,5-bis (1,1,1,3,3,3-hexafluoro-2-methoxy-2-propyl) phenyl] boron, Monoalkyltri (p-nitrophenyl) boron, monoalkyltri (m-nitrophenyl) boron, monoalkyltri (p-butylphenyl) boron, monoalkyltri (m-butylphenyl) boron, monoalkyltri (p-) Butyloxyphenyl) boron, monoalkyltri (m-butyloxyphenyl) boron, monoalkyltri (p-octyloxyphenyl) boron, monoalkyltri (m-octyloxyphenyl) boron (the alkyl group in each of the above examples is n.
- borate compound having four aryl groups in one molecule examples include tetraphenylboron, tetrakis (p-chlorophenyl) boron, tetrakis (p-fluorophenyl) boron, and tetrakis [3,5-bis (trifluoromethyl).
- triazine compound examples include 2,4,6-tris (trichloromethyl) -s-triazine, 2,4,6-tris (tribromomethyl) -s-triazine, 2-methyl-4,6-bis ( Trichloromethyl) -s-triazine, 2-methyl-4,6-bis (tribromomethyl) -s-triazine, 2-phenyl-4,6-bis (trichloromethyl) -s-triazine, 2- (p- Methoxyphenyl) -4,6-bis (trichloromethyl) -s-triazine, 2- (p-methylthiophenyl) -4,6-bis (trichloromethyl) -s-triazine, 2- (p-chlorophenyl) -4 , 6-bis (trichloromethyl) -s-triazine, 2- (2,4-dichlorophenyl) -4,6-bis (trichloromethyl) -s-triazin
- triazine compounds exemplified above particularly preferred are 2,4,6-tris (trichloromethyl) -s-triazine in terms of polymerization activity and 2-phenyl-4 in terms of storage stability. , 6-bis (trichloromethyl) -s-triazine, 2- (p-chlorophenyl) -4,6-bis (trichloromethyl) -s-triazine, and 2- (4-biphenylyl) -4,6-bis ( It is trichloromethyl) -s-triazine.
- the above triazine compound may be used alone or in combination of two or more.
- the copper compound for example, acetylacetone copper, copper acetate (II), copper oleate, copper chloride (II), copper bromide (II) and the like are preferably used.
- Examples of the tin compound include di-n-butyl tin dilaurate, di-n-octyl tin dilaurate, di-n-octyl tin dilaurate, and di-n-butyl tin dilaurate.
- di-n-octyl tin dilaurate and di-n-butyl tin dilaurate are preferable.
- the vanadium compound is preferably an IV-valent and / or V-valent vanadium compound.
- IV-valent and / or V-valent vanadium compounds include divanadium tetraoxide (IV), vanadium acetylacetonate (IV) oxide, vanadyl oxalate (IV), vanadyl sulfate (IV), and oxobis (1-phenyl).
- halogen compound for example, dilauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride, benzyltrimethylammonium chloride, tetramethylammonium chloride, benzyldimethylcetylammonium chloride, dilauryldimethylammonium bromide and the like are preferably used.
- aldehydes include terephthalaldehyde and benzaldehyde derivatives.
- the benzaldehyde derivative include dimethylaminobenzaldehyde, p-methoxybenzaldehyde, p-ethoxybenzaldehyde, pn-octyloxybenzaldehyde and the like. Among them, pn-octyloxybenzaldehyde is preferably used from the viewpoint of curability.
- thiol compound examples include 3-mercaptopropyltrimethoxysilane, 2-mercaptobenzoxazole, decanethiol, and thiobenzoic acid.
- sulfites include sodium sulfite, potassium sulfite, calcium sulfite, ammonium sulfite and the like.
- hydrogen bisulfite examples include sodium bisulfite and potassium bisulfite.
- thiourea compound examples include 1- (2-pyridyl) -2-thiourea, thiourea, methylthiourea, ethylthiourea, N, N'-dimethylthiourea, N, N'-diethylthiourea, N, N'-di.
- N N'-dicyclohexylthiourea, trimethylthiourea, triethylthiourea, tri-n-propylthiourea, tricyclohexylthiourea, tetramethylthiourea, tetraethylthiourea, tetra-n-propylthiourea, Examples thereof include tetracyclohexylthiourea.
- the content thereof is not particularly limited, but from the viewpoint of curability of the obtained dental curable composition, a polymerizable single mass It is preferably 0.001 part by mass or more, more preferably 0.01 part by mass or more, and further preferably 0.02 part by mass or more with respect to 100 parts by mass of the total mass of the body (A). Preferably, it may be 0.03 parts by mass or more, 0.05 parts by mass or more, and further 0.1 parts by mass or more. Further, if the content of the polymerization accelerator (E) is too large, precipitation may occur in the dental curable composition. Therefore, the content of the polymerization accelerator (E) is the polymerizable monomer (A).
- the dental curable composition of the present invention is other than the above-mentioned polymerizable monomer (A), inorganic filler (B), polymerization initiator (C), fluorescent agent (D), and polymerization accelerator (E). Further, if necessary, an additive (F) such as a polymerization inhibitor, an ultraviolet absorber, an antioxidant, an antibacterial agent, a dispersant, a pH adjuster, a pigment, and a dye may be further contained. As the additive (F), one type may be used alone, or two or more types may be used in combination.
- polymerization inhibitor examples include 3,5-di-t-butyl-4-hydroxytoluene, hydroquinone, dibutylhydroquinone, dibutylhydroquinone monomethyl ether, hydroquinone monomethyl ether, 2,6-di-t-butylphenol and the like. , These may be used alone or in combination of two or more.
- Examples of the ultraviolet absorber include 2- (2-hydroxyphenyl) benzotriazole, 2- (2-hydroxy-5-methylphenyl) benzotriazole, 2- (2-hydroxy-5-ethylphenyl) benzotriazole, 2 -(2-Hydroxy-5-propylphenyl) benzotriazole, 2- (2-hydroxy-5-tert-octylphenyl) benzotriazole, 2- (2-hydroxy-3-tert-butyl-5-methylphenyl)- Examples thereof include benzotriazole compounds such as 5-chloro-2H-benzotriazole (tinubin 326), benzotriazole compounds and the like, and these may be used alone or in combination of two or more.
- benzotriazole compounds such as 5-chloro-2H-benzotriazole (tinubin 326), benzotriazole compounds and the like, and these may be used alone or in combination of two or more.
- the method for producing the dental curable composition of the present invention is not particularly limited, and can be obtained by blending each component in a predetermined blending amount.
- the blending order is not particularly limited, and each component may be blended at once, or may be blended in two or more times. Further, if necessary, they may be mixed or kneaded, or may be subjected to a defoaming treatment such as a vacuum defoaming treatment.
- the obtained dental curable composition can be filled into a single container (syringe or the like) to obtain a one-material type (one-paste type) dental curable composition.
- a dental composite resin for example, a composite resin for filling a caries cavity. Abutment construction composite resin, crown composite resin, etc.), denture base resin, denture base lining material, impression material, joint wearing material (for example, resin cement, resin-added glass ionomer cement, etc.), dental It can be preferably used as an adhesive material (for example, an orthodontic adhesive material, a cavity coating adhesive material, etc.), a tooth fissure groove sealing material, a CAD / CAM resin block, a temporary crown, an artificial tooth material, and the like.
- the dental curable composition of the present invention is particularly preferable to be used as a dental composite resin and a CAD / CAM resin block because it has high aesthetics and excellent mechanical strength.
- the present invention includes embodiments in which the above configurations are variously combined within the scope of the technical idea of the present invention as long as the effects of the present invention are exhibited.
- the distance between fulcrums is 20 mm and the crosshead speed is 1 mm / min using a universal testing machine (manufactured by Shimadzu Corporation, trade name "AG-I 100 kN") in accordance with JIS T 6514: 2015 and ISO 4049: 2019.
- the three-point bending strength of the cured product was measured under the above conditions, and the average value of the measured values of each test piece was calculated and used as the bending strength.
- the bending strength is preferably 100 MPa or more, more preferably 110 MPa or more, and even more preferably 120 MPa or more.
- the bending strength is preferably 150 MPa or more, more preferably 165 MPa or more, and even more preferably 180 MPa or more.
- a cover glass and a stainless steel mold having a diameter of 10 mm and a thickness of 1 mm are set on the slide glass, and the dental composite materials obtained in the respective Examples and Comparative Examples are slightly overflowed in the mold. Filled with. Furthermore, a cover glass and then a slide glass were put on it, and a force was applied from above so as to push out the excess dental composite material from the mold. This was irradiated for 10 seconds using a dental visible light irradiator (Pencure 2000, manufactured by Morita Co., Ltd.) and cured, and the cover glass, slide glass, and mold were removed to obtain a cured product test piece. ..
- L * / w is preferably 80 or more, more preferably 82 or more, further preferably 85 or more, particularly preferably 87 or more, and the upper limit is particularly preferable from the viewpoint of aesthetics. May be 98 or less.
- a * / w represents redness, and the lower the value, the stronger the greenness, and the higher the value, the stronger the redness. From the viewpoint of aesthetics, -10 or more is preferable, -9 or more is more preferable, and -8 or more is -8 or more. More preferred. Further, a * / w is preferably 8 or less, more preferably 7 or less, and even more preferably 5 or less.
- b * / w represents yellowness, and the lower the value, the stronger the bluish color, and the higher the value, the stronger the yellow color. From the viewpoint of aesthetics, 0 or more is preferable, 2 or more is more preferable, and 5 or more is further preferable. Further, b * / w is preferably 30 or less, more preferably 25 or less, and even more preferably 20 or less. The higher the ⁇ L *, the higher the transparency, and from the viewpoint of aesthetics, 15 or more is preferable, 20 or more is more preferable, 25 or more is further preferable, and the upper limit may be 50 or less.
- underwater conditions for 30 days are represented by "cured product 37 ° C. for 30 days wet", and the measurement results of the test pieces stored under 60 ° C. dry conditions for 30 days are “cured”.
- the object is expressed as “dry at 60 ° C. for 30 days”, and the measurement result of the test piece exposed in water under xenon lamp irradiation for 24 hours is expressed as "after sun test”.
- the "initial” means a test piece before storage under underwater conditions for a test piece stored under water conditions of 37 ° C. for 30 days, and a drying condition for a test piece stored under dry conditions at 60 ° C. for 30 days. It means a test piece before storage underneath, and for a test piece irradiated with a xenon lamp, it means a test piece before irradiation with a xenon lamp.
- the test piece was exposed to xenon lamp irradiation for 24 hours in the same manner as in the evaluation of the discoloration resistance of the cured product, and the fluorescence score was evaluated in the same manner.
- the fluorescence score is preferably 2.
- Table 1 the measurement result of the test piece before being exposed to xenon lamp irradiation for 24 hours is represented by "initial”, and the measurement result after being exposed to xenon lamp irradiation for 24 hours is represented by "after sun test”.
- the glossiness is preferably 30% or more, more preferably 35% or more, further preferably 40% or more, and particularly preferably 50% or more.
- the dental curable composition is cured using a dental visible light irradiator (Pencure 2000, manufactured by Morita Co., Ltd.), and a test piece ( ⁇ 1.5 mm ⁇ 1.0 mm) of the cured product is cured. ) was prepared.
- the dental mill blank was cut into a plate shape (10 mm ⁇ 10 mm ⁇ 1.0 mm) using a diamond cutter to prepare a test piece.
- the test piece is placed next to the aluminum step wedge in the center of the X-ray film (Carestream Health Co., Ltd., occlusal type "Ultra Speed DF-50”), and a digital X-ray imaging device (Morita Manufacturing Co., Ltd., "Max” Using DC70 ”), X-ray irradiation was performed under the conditions of a target-film distance of 400 mm and a tube voltage of 70 kV. After developing, fixing, and drying the film after irradiation, the image density of the test piece was set to 20 points using an optical densitometer (Made by Kodak, DENSITOMETER, "PDA-85", measurement area (3 mm ⁇ )).
- the X-ray contrast property is preferably 1.0 mm or more, more preferably 1.3 mm or more, further preferably 1.5 mm or more, and may be 2.0 mm or more, or 3.0 mm or more.
- Inorganic filler (B) As the filler, the one obtained in the following production example was used. Moreover, the commercially available product was used as it was.
- the pulverized powder is made hydrophobic by surface treatment with 10 parts by mass of 3-methacryloyloxypropyltrimethoxysilane (KBM-503, manufactured by Shin-Etsu Chemical Co., Ltd.) with respect to 100 parts by mass of the powder, and is an inorganic filler. (B-1) was obtained.
- the average particle size of the obtained inorganic filler (B-1) was 3.0 ⁇ m, and the specific surface area was 146 m 2 / g.
- BHT 3,5-di-t-butyl-4-hydroxytoluene (polymerization inhibitor)
- TIN "Chinubin 326" (manufactured by BASF Japan Ltd.) (ultraviolet absorber)
- Example 1 to 6 and Comparative Examples 1 to 6 (dental composite resin) A dental curable composition was prepared by mixing and kneading the materials and ratios shown in Table 1 at room temperature (23 ° C.) and in a dark place, and vacuum defoaming the homogenized material. Each test was carried out on these dental curable compositions by the method described above. The results are shown in Table 1.
- Example 7 and Comparative Examples 7 and 8 (dental mill blank) A dental curable composition was prepared by mixing and kneading the materials and ratios shown in Table 1 at room temperature (23 ° C.) and in a dark place, and vacuum defoaming the homogenized material. The dental curable composition was then poured into a 20 mm ⁇ 30 mm ⁇ 60 mm rectangular mold and heated at 50 ° C. for 1 hour. Then, while pressurizing at 5 MPa, heat treatment was performed at 150 ° C. for 1 hour to obtain a cured product as a dental mill blank. The cured products of these dental curable compositions were tested by the methods described above. The results are shown in Table 1.
- the dental curable composition of the present invention has a good color tone of the cured product, is also excellent in discoloration resistance, and the fluorescence is not deactivated even after the light resistance test.
- discoloration (yellowing) of the cured product could be suppressed even though alumina was contained as the inorganic filler.
- the dental curable composition of the present invention has high bending strength of the cured product, sufficient gloss is generated by simple polishing, and has good easy polishing property.
- the cured product has sufficient fluorescence, is excellent in aesthetics and durability, has sufficient mechanical strength, and does not impair easy polishing property. It is suitably used as a dental composite resin, a dental mill blank, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dental Preparations (AREA)
Abstract
Description
[1]重合性単量体(A)、無機充填材(B)、重合開始剤(C)、及び蛍光剤(D)を含み、前記蛍光剤(D)が、2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環含有化合物(ベンゾイミダゾール化合物を除く)を含む、歯科用硬化性組成物。
[2]前記2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環含有化合物が、2個のヘテロ原子を含むベンゾ縮合複素6員環含有化合物である蛍光剤(D-1)を含む、[1]に記載の歯科用硬化性組成物。
[3]前記蛍光剤(D-1)が、ベンゾジアジノン骨格を含む化合物及び/又はベンゾオキサジノン骨格を含む化合物を含有する、[2]に記載の歯科用硬化性組成物。
[4]前記ベンゾジアジノン骨格を含む化合物が、下記一般式(5)で表される骨格を含む化合物である、[3]に記載の歯科用硬化性組成物。
[5]前記ベンゾジアジノン骨格を含む化合物が、キナゾリノン骨格を含む化合物(D-1a)である、[3]又は[4]に記載の歯科用硬化性組成物。
[6]前記蛍光剤(D-1)が、ベンゾオキサジノン骨格を含む化合物を含有する、[3]に記載の歯科用硬化性組成物。
[7]前記ベンゾオキサジノン骨格を含む化合物が、下記一般式(6)で表される骨格を含む化合物である、[6]に記載の歯科用硬化性組成物。
[8]前記蛍光剤(D-1)が、下記一般式(1)又は(2)で表される部位を有する化合物である、[2]~[7]のいずれかに記載の歯科用硬化性組成物。
[9]前記蛍光剤(D-1)が、2-(2-ヒドロキシフェニル)-4(1H)-キナゾリノン、2-(2-ヒドロキシフェニル)-4H-3,1-ベンゾオキサジン-4-オン、N-[2-(4(1H)-キナゾリノン-2-イル)フェニル]ベンゼンスルホンアミド、N-[2-(4-オキソ-1,3-ベンゾオキサジン-2-イル)フェニル]ベンゼンスルホンアミド、7-ジメチルアミノ-3-[2-[4-(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、7-ジメチルアミノ-3-[2-[2,3,4,5,6-ペンタフルオロフェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、及び7-ジメチルアミノ-3-[2-[2,4-ビス(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オンからなる群から選ばれる少なくとも1種の化合物を含む、[2]~[7]のいずれかに記載の歯科用硬化性組成物。
[10]前記蛍光剤(D)が、1個の窒素原子と1個の酸素原子を含むベンゾ縮合複素5員環含有化合物である蛍光剤(D-2)をさらに含む、[2]~[9]のいずれかに記載の歯科用硬化性組成物。
[11]前記蛍光剤(D-2)が、ベンゾオキサゾール骨格を含む化合物である蛍光剤(D-2a)である、[10]に記載の歯科用硬化性組成物。
[12]前記蛍光剤(D-2a)が、下記一般式(3)で表される部位を有する化合物である、[11]に記載の歯科用硬化性組成物。
[13]前記蛍光剤(D-2a)が、下記式(12)で表される化合物である、[11]又は[12]に記載の歯科用硬化性組成物。
[15]前記無機充填材(B)の比表面積が、10~300m2/gである、[1]~[14]のいずれかに記載の歯科用硬化性組成物。
[16][1]~[15]のいずれかに記載の歯科用硬化性組成物を用いてなる、歯科用コンポジットレジン。
[17][1]~[15]のいずれかに記載の歯科用硬化性組成物の硬化物を用いてなる、歯科用ミルブランク。
本発明の歯科用硬化性組成物における重合性単量体(A)としては、歯科用硬化性組成物に使用される重合性単量体として公知のものを用いることができ、特にラジカル重合性単量体を好ましく用いることができる。当該ラジカル重合性単量体としては、例えば、α-シアノアクリル酸、(メタ)アクリル酸、α-ハロゲン化アクリル酸、クロトン酸、桂皮酸、ソルビン酸、マレイン酸、イタコン酸等の不飽和カルボン酸のエステル;(メタ)アクリルアミド;(メタ)アクリルアミド誘導体;ビニルエステル類;ビニルエーテル類;モノ-N-ビニル誘導体;スチレン誘導体などが挙げられる。重合性単量体(A)は、1種を単独で使用してもよいし、2種以上を併用してもよい。これらの中でも、不飽和カルボン酸のエステル、(メタ)アクリルアミド誘導体が好ましく、(メタ)アクリル酸エステル、(メタ)アクリルアミド誘導体がより好ましく、(メタ)アクリル酸エステルがさらに好ましい。なお、本明細書において「(メタ)アクリル」との表記は、メタクリルとアクリルの両者を包含する意味で用いられる。また、「(メタ)アクリル系単量体」は、(メタ)アクリル酸エステルと(メタ)アクリルアミド誘導体の両者を包含する意味で用いられる。(メタ)アクリル酸エステル及び(メタ)アクリルアミド誘導体の例を以下に示す。
例えば、メチル(メタ)アクリレート、イソブチル(メタ)アクリレート、ベンジル(メタ)アクリレート、ドデシル(メタ)アクリレート、2-(N,N-ジメチルアミノ)エチル(メタ)アクリレート、2,3-ジブロモプロピル(メタ)アクリレート、3-(メタ)アクリロイルオキシプロピルトリメトキシシラン、11-(メタ)アクリロイルオキシウンデシルトリメトキシシラン、2-ヒドロキシエチル(メタ)アクリレート、3-ヒドロキシプロピル(メタ)アクリレート、4-ヒドロキシブチル(メタ)アクリレート、6-ヒドロキシヘキシル(メタ)アクリレート、10-ヒドロキシデシル(メタ)アクリレート、プロピレングリコールモノ(メタ)アクリレート、グリセリンモノ(メタ)アクリレート、エリスリトールモノ(メタ)アクリレート、フェノキシエチレングリコール(メタ)アクリレート、イソボルニル(メタ)アクリレート、3-フェノキシベンジル(メタ)アクリレート、N-メチロール(メタ)アクリルアミド、N-ヒドロキシエチル(メタ)アクリルアミド、N,N-ビス(ヒドロキシエチル)(メタ)アクリルアミド、N,N-ジメチル(メタ)アクリルアミド、N,N-ジエチル(メタ)アクリルアミド、N,N-ジ-n-プロピル(メタ)アクリルアミド、N-エチル-N-メチル(メタ)アクリルアミド、(メタ)アクリロイルモルホリン、(メタ)アクリロイルオキシドデシルピリジニウムブロミド、(メタ)アクリロイルオキシドデシルピリジニウムクロリド、(メタ)アクリロイルオキシヘキサデシルピリジニウムブロミド、(メタ)アクリロイルオキシヘキサデシルピリジニウムクロリド、エトキシ化-o-フェニルフェノール(メタ)アクリレート、エトキシ化-m-フェニルフェノール(メタ)アクリレート、エトキシ化-p-フェニルフェノール(メタ)アクリレート、プロポキシ化-o-フェニルフェノール(メタ)アクリレート、プロポキシ化-m-フェニルフェノール(メタ)アクリレート、プロポキシ化-p-フェニルフェノール(メタ)アクリレート、o-フェノキシベンジル(メタ)アクリレート、m-フェノキシベンジル(メタ)アクリレート、p-フェノキシベンジル(メタ)アクリレート、2-(o-フェノキシフェニル)エチル(メタ)アクリレート、2-(m-フェノキシフェニル)エチル(メタ)アクリレート、2-(p-フェノキシフェニル)エチル(メタ)アクリレートなどが挙げられる。これらの中でも、得られる歯科用硬化性組成物のペーストの操作性が良く、硬化後の機械的強度に優れる点で、エトキシ化-o-フェニルフェノール(メタ)アクリレート、及びm-フェノキシベンジル(メタ)アクリレートが最も好ましい。
例えば、芳香族系の二官能性の(メタ)アクリル酸エステル、脂肪族系の二官能性の(メタ)アクリル酸エステルなどが挙げられる。
例えば、トリメチロールプロパントリ(メタ)アクリレート、トリメチロールエタントリ(メタ)アクリレート、トリメチロールメタントリ(メタ)アクリレート、ペンタエリスリトールトリ(メタ)アクリレート、ペンタエリスリトールテトラ(メタ)アクリレート、ジペンタエリスリトールトリ(メタ)アクリレート、ジペンタエリスリトールテトラ(メタ)アクリレート、ジペンタエリスリトールペンタ(メタ)アクリレート、N,N’-(2,2,4-トリメチルヘキサメチレン)ビス〔2-(アミノカルボキシ)プロパン-1,3-ジオール〕テトラ(メタ)アクリレート、1,7-ジ(メタ)アクリロイルオキシ-2,2,6,6-テトラ(メタ)アクリロイルオキシメチル-4-オキサヘプタンなどが挙げられる。
本発明の歯科用硬化性組成物は無機充填材(B)を含む。
本発明の歯科用硬化性組成物は重合開始剤(C)を含む。重合開始剤(C)としては、一般工業界で使用されている重合開始剤から選択して使用でき、中でも歯科用途に用いられている重合開始剤が好ましく用いられる。特に、光重合開始剤及び化学重合開始剤が好ましく用いられる。重合開始剤(C)は、1種を単独で用いてもよく、2種以上を適宜組み合わせて使用してもよい。
本発明の歯科用硬化性組成物は、蛍光剤(D)を含む。蛍光剤(D)は、2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環含有化合物(ベンゾイミダゾール化合物を除く)を含む。ヘテロ原子としては、酸素原子、硫黄原子、窒素原子が挙げられ、酸素原子、窒素原子が好ましい。前記ベンゾ縮合複素環含有化合物が含む2個以上のヘテロ原子のうち、少なくとも1個は窒素原子であることが好ましい。前記ベンゾ縮合複素環含有化合物としては、2個のヘテロ原子を含むベンゾ縮合複素6員環含有化合物である蛍光剤(D-1)(以下、単に「蛍光剤(D-1)」ともいう。)が好ましい。前記ベンゾ縮合複素6員環含有化合物は、2個のヘテロ原子を含む複素6員環と、ベンゼン環とが縮合した縮合環を有する。蛍光剤(D-1)としては、ベンゾジアジノン骨格を含む化合物又はベンゾオキサジノン骨格を含む化合物が挙げられる。ベンゾジアジノン骨格を含む化合物としては、キナゾリノン骨格を含む化合物(D-1a)、シンノリノン骨格を含む化合物(D-1b)、フタラジノン骨格を含む化合物(D-1c)、キノキサリノン骨格(D-1d)を含む化合物が挙げられ、キナゾリノン骨格(D-1a)が好ましい。前記蛍光剤(D-1)を含むことで、十分な蛍光性を有し、審美性が高く、口腔内環境下や加速加熱条件下、キセノンランプ光曝露条件下における耐変色性に優れ、これらのような条件下においても蛍光性が失活しない歯科用コンポジットレジン及び歯科用ミルブランクなどとして好適な歯科用硬化性組成物、及びその硬化物となる。本発明の歯科用硬化性組成物、及びその硬化物によって、上記のような優れた効果が奏される理由は必ずしも定かではないが、ベンゾジアジノン骨格、又はベンゾオキサジノン骨格等の、2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環骨格の安定性が高いためであると考えられる。
2-(2-ヒドロキシフェニル)-4(1H)-キナゾリノン、
2-(2-ヒドロキシフェニル)-4H-3,1-ベンゾオキサジン-4-オン、
N-[2-(4(1H)-キナゾリノン-2-イル)フェニル]ベンゼンスルホンアミド、
N-[2-(4-オキソ-1,3-ベンゾオキサジン-2-イル)フェニル]ベンゼンスルホンアミド、
7-ジメチルアミノ-3-[2-[4-(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、
7-ジメチルアミノ-3-[2-[2,3,4,5,6-ペンタフルオロフェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、
7-ジメチルアミノ-3-[2-[2,4-ビス(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、
が好ましく、
2-(2-ヒドロキシフェニル)-4(1H)-キナゾリノン、
N-[2-(4-オキソ-1,3-ベンゾオキサジン-2-イル)フェニル]ベンゼンスルホンアミド、
がより好ましい。
1,4-ビス(2-ベンゾオキサゾリル)ナフタレン、
4,4’-ビス(2-ベンゾオキサゾリル)スチルベン,1,2-ビス(5-メチルベンゾオキサゾール-2-イル)エテン、
4,4’-ビス(5-メチル-2-ベンゾオキサゾリル)スチルベン、
4-(2-ベンゾオキサゾリル)-4’-(5-メチル-2-ベンゾオキサゾリル)スチルベン、
2,5-ビス(ベンゾオキサゾール-2-イル)チオフェン、
2,5-ビス(5-tert-ブチル-2-ベンゾオキサゾリル)チオフェン、
が好ましい。
本発明の歯科用硬化性組成物は、重合促進剤(E)をさらに含んでいてもよい。重合促進剤としては、アミン類、スルフィン酸及びその塩、バルビツール酸誘導体、ボレート化合物、トリアジン化合物、銅化合物、錫化合物、バナジウム化合物、ハロゲン化合物、アルデヒド類、チオール化合物、亜硫酸塩、亜硫酸水素塩、チオ尿素化合物などが挙げられる。重合促進剤(E)は、1種を単独で使用してもよく、2種以上を併用してもよい。ある好適な実施形態では、重合開始剤(C)が光重合開始剤を含み、さらに重合促進剤(E)を含み、前記重合促進剤(E)が第3級アミンである、歯科用硬化性組成物が挙げられる。前記第3級アミンとしては、第3級芳香族アミンが好ましい。前記好適な実施形態の歯科用硬化性組成物は、歯科用コンポジットレジンとしてより好適である。
本発明の歯科用硬化性組成物は、上記した重合性単量体(A)、無機充填材(B)、重合開始剤(C)、蛍光剤(D)、並びに重合促進剤(E)以外にも、必要に応じて、重合禁止剤、紫外線吸収剤、酸化防止剤、抗菌剤、分散剤、pH調整剤、顔料、染料等の添加剤(F)を、さらに含んでいてもよい。添加剤(F)は、1種を単独で使用してもよく、2種以上を併用してもよい。
本発明の歯科用硬化性組成物の製造方法に特に制限はなく、各成分を所定の配合量で配合することにより得ることができる。この際の配合順序に特に制限はなく、各成分を一括して配合してもよいし、2回以上に分けて配合してもよい。また、必要に応じて混合ないし練合したり、あるいは、真空脱泡処理等の脱泡処理を施したりしてもよい。得られた歯科用硬化性組成物は、単一の容器(シリンジ等)に充填するなどして、1材型(1ペースト型)の歯科用硬化性組成物とすることができる。
本発明の歯科用硬化性組成物、及びその硬化物の用途に特に制限はなく、各種歯科材料として用いることができ、具体的には、歯科用コンポジットレジン(例えば、齲蝕窩洞充填用コンポジットレジン、支台築造用コンポジットレジン、歯冠用コンポジットレジン等)、義歯床用レジン、義歯床用裏装材、印象材、合着用材料(例えば、レジンセメント、レジン添加型グラスアイオノマーセメント等)、歯科用接着材(例えば、歯列矯正用接着材、窩洞塗布用接着材等)、歯牙裂溝封鎖材、CAD/CAM用レジンブロック、テンポラリークラウン、人工歯材料などとして好ましく用いることができる。これらの中でも、本発明の歯科用硬化性組成物は、審美性が高く、機械的強度も優れることから、歯科用コンポジットレジン、及びCAD/CAM用レジンブロックとして用いることが特に好ましい。
〔充填材の平均粒子径〕
下記の充填材について、エタノールを分散媒とし、レーザー回折式粒度分布測定装置(株式会社島津製作所製「SALD-2300」)を用いて体積基準で測定、あるいは、走査型電子顕微鏡(SU3500、株式会社日立ハイテクノロジーズ製)を使用して、平均粒子径を測定した(N=1)。
下記の各製造例で得られた無機充填材について、電気炉にて450℃で4時間処理して灰化した後に、比表面積測定装置(マイクロトラック・ベル株式会社製「BELSORP-mini II」)を用い、100℃で2時間真空脱揮した後、吸着ガス:窒素、測定温度:77Kの条件でBET法に基づき無機充填材の比表面積を測定した(N=1)。なお当該測定においては、飽和蒸気圧P0(kPa)に対する吸着平衡圧P(kPa)の比(P/P0)が0.05~0.3の範囲にある吸着側等温線上の5点を用いたBET多点法による解析を採用した。
製造した各実施例及び比較例の歯科用硬化性組成物を真空脱泡後、ステンレス製金型(寸法:2mm×2mm×25mm)に充填し、上下をスライドガラスで圧接し、歯科用可視光線照射器(ペンキュアー2000、株式会社モリタ製)で1点10秒、片面を5点ずつ、両面に光を照射して硬化させた。各実施例及び比較例について、硬化物を試験片として5本ずつ作製した。硬化物の試験片を金型から取り出した後、37℃の蒸留水中に24時間保管した。各試験片について、JIS T 6514:2015及びISO4049:2019に従って、万能試験機(株式会社島津製作所製、商品名「AG-I 100kN」)を用いて、支点間距離20mm、クロスヘッドスピード1mm/分の条件下で硬化物の試験片の3点曲げ強さを測定し、各試験片の測定値の平均値を算出し、曲げ強さとした。曲げ強さは100MPa以上が好ましく、110MPa以上がより好ましく、120MPa以上がさらに好ましい。
製造した各実施例及び比較例の歯科用硬化性組成物の硬化物からダイヤモンドカッターを用いて、試験片(1.2mm×4mm×14mm)を10本作製し、37℃の蒸留水中に24時間浸漬した。各試験片について、JDMAS 245:2017(CAD/CAM冠用歯科切削加工用レジン材料)に従って、万能試験機(株式会社島津製作所製、商品名「AG-I 100kN」)を用いて、支点間距離12mm、クロスヘッドスピード1mm/分の条件下で硬化物の試験片の3点曲げ強さを測定し、各試験片の測定値の平均値を算出し、曲げ強さとした(N=10)。曲げ強さは150MPa以上が好ましく、165MPa以上がより好ましく、180MPa以上がさらに好ましい。
スライドガラス上に、カバーガラス、さらにその上に直径10mm、厚さ1mmのステンレス製金型をセットし、該金型内に各実施例、比較例で得られた歯科用複合材料を少し溢れる程度に充填した。さらにその上からカバーガラス、続いてスライドガラスをかぶせ、金型から余剰な歯科用複合材料を押し出すように上から力を加えた。これを、歯科用可視光線照射器(ペンキュアー2000、株式会社モリタ製)を用いて10秒間照射し硬化させ、カバーガラス及びスライドガラス、金型を除去することで硬化物の試験片を得た。
製造した各実施例及び比較例の歯科用硬化性組成物の硬化物からダイヤモンドカッターを用いて、板状試験片(10mm×10mm×1.2mm)を切り出した後、平滑面を#1500研磨紙、#2000研磨紙、#3000研磨紙の順に乾燥条件下で研磨し、最終的に厚さを1.0mmに調整した。この試験片を、分光色差計(SE6000、日本電色工業株式会社製)を用いて歯科用コンポジットレジンの場合と同様に色調を測定した(N=1)。
歯科用コンポジットレジン及び歯科用ミルブランクのいずれの場合においても、硬化物の色調の評価と同様の方法で試験片を3枚作製し、同様の方法でL*/w、a*/w及びb*/wを測定し、これを初期の明度、及び色度とした。この各試験片の内1枚は37℃水中条件下、もう1枚は60℃乾燥条件下にて、それぞれ30日間保管した。また、もう1枚は、促進耐候性試験機(SOLARBOX 1500e、CO.FO.ME.GRA社製)を用いて、水中、照度150,000lxのキセノンランプ照射下に24時間暴露し、耐久試験とした。これらの耐久試験後の各試験片のL*/w、a*/w及びb*/wを測定し、初期の明度、及び色度との差ΔL*、Δa*及びΔb*を求めた。さらに、色差ΔE*={(ΔL*)2+(Δa*)2+(Δb*)2}1/2を求め、これを各耐久試験後の耐変色性の指標とした。ΔE*が低いほど耐変色性が高いことを意味し、7以下が好ましく、6以下がより好ましく、5以下がさらに好ましい。表1では、37℃水中条件下で30日間保管した試験片の測定結果を「硬化物37℃30日間wet」で表し、60℃乾燥条件下で30日間保管した試験片の測定結果を「硬化物60℃30日間dry」で表し、水中、キセノンランプ照射下に24時間暴露した試験片の測定結果を「サンテスト後」で表す。前記「初期」は、37℃水中条件下で30日間保管した試験片については水中条件下での保管前の試験片を意味し、60℃乾燥条件下で30日間保管した試験片については乾燥条件下での保管前の試験片を意味し、キセノンランプを照射した試験片についてはキセノンランプ照射前の試験片を意味する。
歯科用コンポジットレジン及び歯科用ミルブランクのいずれの場合においても、硬化物の色調の評価と同様の方法で硬化物の試験片を1枚作製した。また、人抜去歯を研磨し、厚さ1mmの人歯試験片を作製した。ブラックライト(FL20S BLB,東芝ライテック株式会社製)照射下で硬化物の試験片と人歯試験片を観察し、蛍光強度を目視で比較し、スコアをつけた。すなわち、スコアは硬化物の試験片の蛍光強度が、人歯試験片と同等であれば「2」、蛍光強度が劣っていれば「1」、蛍光が見られなければ「0」とした。また、硬化物の耐変色性の評価と同様の方法で、この試験片に対してキセノンランプ照射下に24時間暴露し、同様に蛍光性のスコアを評価した。蛍光性のスコアは2であることが好ましい。表1では、キセノンランプ照射下に24時間暴露する前の試験片の測定結果を「初期」で表し、キセノンランプ照射下に24時間暴露した後の測定結果を「サンテスト後」で表す。
歯科用コンポジットレジンについては、リテトラフルオロエチレン製の型(内径10mm×厚さ2.0mm)に各実施例及び比較例で得られた歯科用硬化性組成物を充填し、歯科用可視光線照射器(ペンキュアー2000、株式会社モリタ製)で10秒間光照射を行い、硬化物を型から取り出し試験片とした。歯科用ミルブランクについては、ダイヤモンドカッターを用いて、板状(10mm×10mm×2.0mm)に切り出し、試験片とした。これらの試験片の平滑面を、乾燥条件下、#600研磨紙にて研磨した。さらに、技工用エンジンとして「Volvere RX」(NSK社製)を使用し、湿潤条件下、シリコンポイント茶色(株式会社松風製「M2 HP」)を用いて回転速度約5,000rpmで10秒間研磨し、続けてシリコンポイント青色(株式会社松風製「M3 HP」)を用いて回転速度約5,000rpmで10秒間研磨した。その後、この研磨面の光沢を光沢度計(日本電色工業株式会社製「VG-2000」、測定角度60度)を用いて測定し、鏡を100%とした時の割合(光沢度)を求め、これを硬化物の易研磨性の指標とした(N=3)。光沢度は、30%以上であることが好ましく、35%以上であることがより好ましく、40%以上であることがさらに好ましく、50%以上であることが特に好ましい。
歯科用コンポジットレジンについては、歯科用硬化性組成物を、歯科用可視光線照射器(ペンキュアー2000、株式会社モリタ製)を用いて硬化させ、硬化物の試験片(φ1.5mm×1.0mm)を作製した。歯科用ミルブランクについては、ダイヤモンドカッターを用いて、板状(10mm×10mm×1.0mm)に切り出し、試験片とした。該試験片をアルミステップウェッジと隣り合わせてX線フィルム(ケアストリームヘルス株式会社製、咬合型「ウルトラスピードDF-50」)の中央に位置させ、デジタルX線撮影装置(モリタ製作所社製、「マックスDC70」)を用いて、ターゲット-フィルム間距離400mm、管電圧70kVの条件でX線照射を行った。照射後の前記フィルムを現像・定着・乾燥させた後に、光学濃度計(コダック社製、DENSITOMETER、「PDA-85」、測定エリア(3mmφ))を用いて、前記試験片の画像濃度を20点測定し、前記試験片の画像濃度と前記アルミステップウェッジの各厚みの画像濃度とを比較することにより、アルミ板の厚みに相当するX線造影性を求めた(N=1)。X線造影性は1.0mm以上が好ましく、1.3mm以上がより好ましく、1.5mm以上がさらに好ましく、2.0mm以上であってもよく、3.0mm以上であってもよい。
(重合性単量体(A))
D2.6E:2,2-ビス(4-メタクリロイルオキシポリエトキシフェニル)プロパン(エチレンオキシ基の平均付加モル数:2.6)
Bis-GMA:2,2-ビス〔4-(3-メタクリロイルオキシ-2-ヒドロキシプロポキシ)フェニル〕プロパン
UDMA:2,2,4-トリメチルヘキサメチレンビス(2-カルバモイルオキシエチル)ジメタクリレート
3G:トリエチレングリコールジメタクリレート
TCDDMA:トリシクロデカンジメタノールジメタクリレート
充填材としては、下記の製造例で得られたものを用いた。また、市販品はそのまま用いた。
・B-1(シリカ-ジルコニア)の製造
オキシ硝酸ジルコニウム32.5gを325gの蒸留水に溶解した。この溶液を撹拌しながら、市販のシリカゾル(日産化学株式会社製「スノーテックスOL」)425gを徐々に加えて混合液を得た。この混合液を凍結乾燥して得られた混合粉末を、アルミナ坩堝に入れ、電気炉にて昇温速度2℃/分で昇温した後に600℃で1時間焼成し、次いで、これを遊星型ボールミル(フリッチュ社製、「クラシックラインP-6」、ジルコニアボール)にて240分間粉砕した。粉砕後の粉末について、粉末100質量部に対して10質量部の3-メタクリロイルオキシプロピルトリメトキシシラン(KBM-503、信越化学工業株式会社製)で表面処理することにより疎水化して、無機充填材(B-1)を得た。得られた無機充填材(B-1)の平均粒子径は3.0μmであり、比表面積は146m2/gであった。
・B-2(アルミナ)の製造
アルミナ微粉(AEROXIDE Alu C、日本アエロジル株式会社製)100質量部に対して20質量部のγ-メタクリロキシプロピルトリメトキシシラン(KBM-503、信越化学工業株式会社製)を用いて表面処理を行い、無機充填材(B-2)を得た。得られた無機充填材(B-2)の平均粒子径は0.02μmであり、100m2/gであった。
・B-3(バリウムガラス)の製造
市販のバリウムガラス(GM27884 NanoFine180、ショット社製)100質量部、3-メタクリロイルオキシプロピルトリメトキシシラン(KBM-503、信越化学工業株式会社製)7質量部、及びトルエン173質量部を三口フラスコに入れ、2時間、室温下で撹拌した。トルエンを減圧下で留去した後、40℃で16時間真空乾燥を行い、さらに90℃で3時間加熱し、表面処理層が設けられた無機充填材(B-3)を得た。得られた無機充填材(B-3)の平均粒子径は0.2μmであり、比表面積は35m2/gであった。
・B-4(有機無機複合充填材)の製造
予め重合開始剤としてアゾビスイソブチロニトリル(AIBN)を1質量%溶解した、Bis-GMAと3Gの重合性単量体混合物(質量比1:1)100質量部に対して、無機充填材として上記で製造した無機充填材(B-3)を100質量部添加、混合しペースト化した。これを100℃、減圧雰囲気下で5時間加熱重合した。得られた重合硬化物を、振動ボールミルを用いて、平均粒子径が約5μmとなるまで粉砕した。得られた粉末100質量部に対して、γ-メタクリロイルオキシプロピルトリメトキシシラン(KBM-503、信越化学工業株式会社製)2質量%含有エタノール溶液中、90℃で5時間還流することで表面処理を行ない、有機無機複合充填材である無機充填材(B-4)を得た。得られた無機充填材(B-4)の平均粒子径は5.2μmであり、比表面積は35m2/gであった。
・B-5(シリカ-イッテルビア)の製造
市販のシリカ-イッテルビウム酸化物水分散液(SG-YBSO30SW、Sukgyung AT社製)中の水を、エバポレーターを用いて留去し、得られた固体成分を遊星型ボールミル(フリッチュ社製、「クラシックラインP-6」、ジルコニアボール)により180分間粉砕した。得られた粉体を800℃に設定した電気炉にて1時間焼成し、これをさらに前記遊星型ボールミルにて180分間粉砕した。得られた粉末100質量部に対して10質量部の3-メタクリロイルオキシプロピルトリメトキシシラン(KBM-503、信越化学工業株式会社製)で表面処理することにより疎水化して、無機充填材(B-5)を得た。得られた無機充填材(B-5)の平均粒子径は5.7μmであり、比表面積は95.8m2/gであった。
シリカコートフッ化イッテルビウム(SG-YBF100WSCMP10、Sukgyung AT社製)をそのまま用いた。平均粒子径は100nmであり、比表面積は14.2m2/gであった。
CQ:カンファーキノン
TPO:2,4,6-トリメチルベンゾイルジフェニルホスフィンオキシド
THP:1,1,3,3-テトラメチルブチルヒドロペルオキシド
・D-1-1:2-(2ーヒドロキシフェニル)-4(1H)-キナゾリノン(式(9))
・D-3-1:2,5-ジヒドロキシテレフタル酸ジエチル
PDE:4-(N,N-ジメチルアミノ)安息香酸エチル
BHT:3,5-ジ-t-ブチル-4-ヒドロキシトルエン(重合禁止剤)
TIN:「チヌビン326」(BASFジャパン株式会社製)(紫外線吸収剤)
表1に記載された材料及び割合にて、これらを常温(23℃)及び暗所で混合練和し、均一にしたものを真空脱泡することにより、歯科用硬化性組成物を調製した。これらの歯科用硬化性組成物について、上記した方法で各試験を行った。結果を表1に示した。
表1に記載された材料及び割合にて、これらを常温(23℃)及び暗所で混合練和し、均一にしたものを真空脱泡することにより、歯科用硬化性組成物を調製した。次いで、該歯科用硬化性組成物を20mm×30mm×60mmの長方体型の金型に流し込み、50℃で1時間加熱した。その後、5MPaで加圧しながら、150℃で1時間加熱処理を行い、歯科用ミルブランクとして硬化物を得た。これらの歯科用硬化性組成物の硬化物について、上記した方法で各試験を行った。結果を表1に示した。
Claims (17)
- 重合性単量体(A)、無機充填材(B)、重合開始剤(C)、及び蛍光剤(D)を含み、前記蛍光剤(D)が、2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環含有化合物(ベンゾイミダゾール化合物を除く)を含む、歯科用硬化性組成物。
- 前記2個以上のヘテロ原子を含む9~11員ベンゾ縮合複素環含有化合物が、2個のヘテロ原子を含むベンゾ縮合複素6員環含有化合物である蛍光剤(D-1)を含む、請求項1に記載の歯科用硬化性組成物。
- 前記蛍光剤(D-1)が、ベンゾジアジノン骨格を含む化合物及び/又はベンゾオキサジノン骨格を含む化合物を含有する、請求項2に記載の歯科用硬化性組成物。
- 前記ベンゾジアジノン骨格を含む化合物が、キナゾリノン骨格を含む化合物(D-1a)である、請求項3又は4に記載の歯科用硬化性組成物。
- 前記蛍光剤(D-1)が、ベンゾオキサジノン骨格を含む化合物を含有する、請求項3に記載の歯科用硬化性組成物。
- 前記蛍光剤(D-1)が、2-(2-ヒドロキシフェニル)-4(1H)-キナゾリノン、2-(2-ヒドロキシフェニル)-4H-3,1-ベンゾオキサジン-4-オン、N-[2-(4(1H)-キナゾリノン-2-イル)フェニル]ベンゼンスルホンアミド、N-[2-(4-オキソ-1,3-ベンゾオキサジン-2-イル)フェニル]ベンゼンスルホンアミド、7-ジメチルアミノ-3-[2-[4-(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、7-ジメチルアミノ-3-[2-[2,3,4,5,6-ペンタフルオロフェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オン、及び7-ジメチルアミノ-3-[2-[2,4-ビス(トリフルオロメチル)フェニル]エテニル]-2H-1,4-ベンゾオキサジン-2-オンからなる群から選ばれる少なくとも1種の化合物を含む、請求項2~7のいずれか1項に記載の歯科用硬化性組成物。
- 前記蛍光剤(D)が、1個の窒素原子と1個の酸素原子を含むベンゾ縮合複素5員環含有化合物である蛍光剤(D-2)をさらに含む、請求項2~9のいずれか1項に記載の歯科用硬化性組成物。
- 前記蛍光剤(D-2)が、ベンゾオキサゾール骨格を含む化合物である蛍光剤(D-2a)である、請求項10に記載の歯科用硬化性組成物。
- 前記無機充填材(B)が、酸化ジルコニウム、酸化アルミニウム、酸化イッテルビウム、及びフッ化イッテルビウムからなる群より選ばれる少なくとも一種の金属化合物を含む無機充填材である、請求項1~13のいずれか1項に記載の歯科用硬化性組成物。
- 前記無機充填材(B)の比表面積が、10~300m2/gである、請求項1~14のいずれか1項に記載の歯科用硬化性組成物。
- 請求項1~15のいずれか1項に記載の歯科用硬化性組成物を用いてなる、歯科用コンポジットレジン。
- 請求項1~15のいずれか1項に記載の歯科用硬化性組成物の硬化物を用いてなる、歯科用ミルブランク。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021565633A JP7663511B2 (ja) | 2019-12-17 | 2020-12-16 | 蛍光性を有する歯科用硬化性組成物及びその硬化物 |
| EP20903363.8A EP4079280A4 (en) | 2019-12-17 | 2020-12-16 | FLUORESCENT CURABLE DENTAL COMPOSITION AND CURED PRODUCT THEREOF |
| US17/786,071 US12465559B2 (en) | 2019-12-17 | 2020-12-16 | Fluorescent curable dental composition and cured product thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-227752 | 2019-12-17 | ||
| JP2019227752 | 2019-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021125246A1 true WO2021125246A1 (ja) | 2021-06-24 |
Family
ID=76477602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2020/047055 Ceased WO2021125246A1 (ja) | 2019-12-17 | 2020-12-16 | 蛍光性を有する歯科用硬化性組成物及びその硬化物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12465559B2 (ja) |
| EP (1) | EP4079280A4 (ja) |
| JP (1) | JP7663511B2 (ja) |
| WO (1) | WO2021125246A1 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023127794A1 (ja) * | 2021-12-27 | 2023-07-06 | ||
| WO2023191112A1 (ja) | 2022-04-01 | 2023-10-05 | クラレノリタケデンタル株式会社 | 良好な色調適合性を有する歯科用硬化性組成物 |
| WO2024150826A1 (ja) * | 2023-01-13 | 2024-07-18 | クラレノリタケデンタル株式会社 | 歯科用組成物 |
| EP4434512A4 (en) * | 2021-11-15 | 2026-04-15 | Tokuyama Dental Corp | HARDCIFYABLE DENTAL COMPOSITION |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240358604A1 (en) * | 2023-04-27 | 2024-10-31 | Kurt R. Hulse | Light Emitting Dental Compositions and Methods of Using the Same |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02233605A (ja) | 1989-01-30 | 1990-09-17 | Dentsply Internatl Inc | 放射線不透過性、フッ化物放出性、可視光線硬化性歯科用複合体並びに該複合体中での特定充填材の使用 |
| JPH10245525A (ja) | 1997-03-03 | 1998-09-14 | Tokuyama Corp | 接着性組成物 |
| JPH1192461A (ja) | 1997-09-19 | 1999-04-06 | Tokuyama Corp | ジスルフィド化合物および金属表面処理剤 |
| JP2003096122A (ja) | 2001-09-21 | 2003-04-03 | Tokuyama Corp | ラジカル重合触媒 |
| JP2009215443A (ja) * | 2008-03-11 | 2009-09-24 | Osaka Prefecture Univ | ベンゾオキサジノン系化合物、色素および有機電界発光素子 |
| JP2009280673A (ja) | 2008-05-21 | 2009-12-03 | Tokuyama Dental Corp | 光重合性組成物 |
| JP2010222466A (ja) | 2009-03-23 | 2010-10-07 | Noritake Co Ltd | 蛍光性ジルコニア材料 |
| JP2013234259A (ja) * | 2012-05-09 | 2013-11-21 | Riso Kagaku Corp | 孔版印刷用w/oエマルションインク |
| JP2014507410A (ja) * | 2011-01-13 | 2014-03-27 | ビーエーエスエフ ソシエタス・ヨーロピア | 新規蛍光化合物 |
| JP2015063490A (ja) * | 2013-09-25 | 2015-04-09 | クラレノリタケデンタル株式会社 | 有機蛍光色素に好適な化合物及びそれを含む硬化性組成物 |
| JP2017141188A (ja) | 2016-02-10 | 2017-08-17 | 株式会社トクヤマデンタル | 硬化性組成物 |
| US20190315713A1 (en) * | 2016-10-13 | 2019-10-17 | Universite De Geneve | New compounds and uses thereof for detection of target molecules in a sample |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3388670B2 (ja) | 1995-04-19 | 2003-03-24 | 株式会社トクヤマ | 可視光線重合開始剤および可視光線重合性組成物 |
| US5795497A (en) * | 1996-04-18 | 1998-08-18 | Tokuyama Corporation | Thiouracil derivatives and metal surface-treating agent comprising thereof |
| JP3404714B2 (ja) | 1996-04-18 | 2003-05-12 | 株式会社トクヤマ | チオウラシル誘導体 |
| DE60135302D1 (de) | 2000-08-22 | 2008-09-25 | Tokuyama Corp | Aushärtbare dentalzusammensetzung |
| JP4993053B2 (ja) | 2001-02-27 | 2012-08-08 | 株式会社トクヤマ | 歯科用硬化性組成物 |
| BRPI0914427C8 (pt) | 2008-10-15 | 2018-07-24 | 3M Innovative Properties Co | composição dental endurecível |
-
2020
- 2020-12-16 WO PCT/JP2020/047055 patent/WO2021125246A1/ja not_active Ceased
- 2020-12-16 US US17/786,071 patent/US12465559B2/en active Active
- 2020-12-16 JP JP2021565633A patent/JP7663511B2/ja active Active
- 2020-12-16 EP EP20903363.8A patent/EP4079280A4/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02233605A (ja) | 1989-01-30 | 1990-09-17 | Dentsply Internatl Inc | 放射線不透過性、フッ化物放出性、可視光線硬化性歯科用複合体並びに該複合体中での特定充填材の使用 |
| JPH10245525A (ja) | 1997-03-03 | 1998-09-14 | Tokuyama Corp | 接着性組成物 |
| JPH1192461A (ja) | 1997-09-19 | 1999-04-06 | Tokuyama Corp | ジスルフィド化合物および金属表面処理剤 |
| JP2003096122A (ja) | 2001-09-21 | 2003-04-03 | Tokuyama Corp | ラジカル重合触媒 |
| JP2009215443A (ja) * | 2008-03-11 | 2009-09-24 | Osaka Prefecture Univ | ベンゾオキサジノン系化合物、色素および有機電界発光素子 |
| JP2009280673A (ja) | 2008-05-21 | 2009-12-03 | Tokuyama Dental Corp | 光重合性組成物 |
| JP2010222466A (ja) | 2009-03-23 | 2010-10-07 | Noritake Co Ltd | 蛍光性ジルコニア材料 |
| JP2014507410A (ja) * | 2011-01-13 | 2014-03-27 | ビーエーエスエフ ソシエタス・ヨーロピア | 新規蛍光化合物 |
| JP2013234259A (ja) * | 2012-05-09 | 2013-11-21 | Riso Kagaku Corp | 孔版印刷用w/oエマルションインク |
| JP2015063490A (ja) * | 2013-09-25 | 2015-04-09 | クラレノリタケデンタル株式会社 | 有機蛍光色素に好適な化合物及びそれを含む硬化性組成物 |
| JP2017141188A (ja) | 2016-02-10 | 2017-08-17 | 株式会社トクヤマデンタル | 硬化性組成物 |
| US20190315713A1 (en) * | 2016-10-13 | 2019-10-17 | Universite De Geneve | New compounds and uses thereof for detection of target molecules in a sample |
Non-Patent Citations (2)
| Title |
|---|
| J. MORITA CORP., PENCURE, 2000 |
| See also references of EP4079280A4 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4434512A4 (en) * | 2021-11-15 | 2026-04-15 | Tokuyama Dental Corp | HARDCIFYABLE DENTAL COMPOSITION |
| JPWO2023127794A1 (ja) * | 2021-12-27 | 2023-07-06 | ||
| WO2023127794A1 (ja) * | 2021-12-27 | 2023-07-06 | クラレノリタケデンタル株式会社 | 歯科用硬化性組成物及び基材と樹脂層を含む歯科用補綴物 |
| WO2023191112A1 (ja) | 2022-04-01 | 2023-10-05 | クラレノリタケデンタル株式会社 | 良好な色調適合性を有する歯科用硬化性組成物 |
| WO2024150826A1 (ja) * | 2023-01-13 | 2024-07-18 | クラレノリタケデンタル株式会社 | 歯科用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2021125246A1 (ja) | 2021-06-24 |
| US12465559B2 (en) | 2025-11-11 |
| EP4079280A4 (en) | 2023-12-06 |
| US20230075693A1 (en) | 2023-03-09 |
| JP7663511B2 (ja) | 2025-04-16 |
| EP4079280A1 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7663511B2 (ja) | 蛍光性を有する歯科用硬化性組成物及びその硬化物 | |
| US6787629B2 (en) | Dental resin materials, method of manufacture, and uses thereof | |
| JP7426343B2 (ja) | 歯科用組成物 | |
| WO2020218446A1 (ja) | 歯科修復用硬化性組成物 | |
| JP6831762B2 (ja) | 複合酸化物粒子及び該複合酸化物粒子を含む歯科用複合材料 | |
| JP2026042040A (ja) | 良好な色調適合性を有する歯科用硬化性組成物 | |
| US9296891B2 (en) | Dental resin materials, method of manufacture, and uses thereof | |
| JP6846167B2 (ja) | 歯科用ミルブランクアセンブリ | |
| JP7464615B2 (ja) | 歯科用硬化性組成物 | |
| JP7105063B2 (ja) | 歯科材料に好適な重合性単量体及びそれを用いた歯科用組成物 | |
| JP6429310B2 (ja) | イオン放出機能性複合微粒子 | |
| CN109890344B (zh) | 分包型的牙科用胶合剂 | |
| JP5943672B2 (ja) | 歯科用複合化無機充填材 | |
| JP2020176089A (ja) | 歯科用組成物 | |
| WO2021132463A1 (ja) | 歯科用修復材組成物 | |
| EP4505992A1 (en) | Dental curable composition having favorable color compatibility | |
| JP6145012B2 (ja) | 有機蛍光色素に好適な化合物及びそれを含む硬化性組成物 | |
| WO2023058771A1 (ja) | 分包型の歯科用硬化性組成物 | |
| JP2019116431A (ja) | 耐水性ミルブランク | |
| JP7308612B2 (ja) | プレポリマー及びそれを用いた歯科用組成物 | |
| JP2020029438A (ja) | 歯科用硬化性組成物及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20903363 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2021565633 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020903363 Country of ref document: EP Effective date: 20220718 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 17786071 Country of ref document: US |


































